ZA200508159B - Pharmaceutical compositions of CETP inhibitors - Google Patents
Pharmaceutical compositions of CETP inhibitors Download PDFInfo
- Publication number
- ZA200508159B ZA200508159B ZA200508159A ZA200508159A ZA200508159B ZA 200508159 B ZA200508159 B ZA 200508159B ZA 200508159 A ZA200508159 A ZA 200508159A ZA 200508159 A ZA200508159 A ZA 200508159A ZA 200508159 B ZA200508159 B ZA 200508159B
- Authority
- ZA
- South Africa
- Prior art keywords
- phenyl
- group
- substituted
- isopentylcyclohexanecarbonylamino
- transfer protein
- Prior art date
Links
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title claims description 152
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 74
- -1 S-carboxythiopentanoate Chemical compound 0.000 claims description 422
- 150000001875 compounds Chemical class 0.000 claims description 139
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 claims description 127
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims description 90
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims description 90
- 125000000217 alkyl group Chemical group 0.000 claims description 87
- 230000000694 effects Effects 0.000 claims description 87
- 235000013305 food Nutrition 0.000 claims description 74
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 73
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 46
- 238000011282 treatment Methods 0.000 claims description 44
- 239000000654 additive Substances 0.000 claims description 41
- 230000000996 additive effect Effects 0.000 claims description 35
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 31
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 30
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 27
- 125000002252 acyl group Chemical group 0.000 claims description 24
- 241000124008 Mammalia Species 0.000 claims description 23
- FFAADXOKPZHULO-UHFFFAOYSA-N 2-methylpropanethioic s-acid Chemical compound CC(C)C(S)=O FFAADXOKPZHULO-UHFFFAOYSA-N 0.000 claims description 20
- 125000005843 halogen group Chemical group 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 125000003277 amino group Chemical group 0.000 claims description 17
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 15
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 13
- 229960000913 crospovidone Drugs 0.000 claims description 13
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 13
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 13
- YZQLWPMZQVHJED-UHFFFAOYSA-N 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester Chemical group C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 125000004414 alkyl thio group Chemical group 0.000 claims description 10
- JHSXHKMJBWOMRU-UHFFFAOYSA-N 2,2-dimethylpropanethioic s-acid Chemical compound CC(C)(C)C(S)=O JHSXHKMJBWOMRU-UHFFFAOYSA-N 0.000 claims description 9
- 201000001320 Atherosclerosis Diseases 0.000 claims description 8
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims description 8
- 125000005110 aryl thio group Chemical group 0.000 claims description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- 208000029078 coronary artery disease Diseases 0.000 claims description 8
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 239000000651 prodrug Substances 0.000 claims description 7
- 229940002612 prodrug Drugs 0.000 claims description 7
- 150000003573 thiols Chemical class 0.000 claims description 7
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 206010021024 Hypolipidaemia Diseases 0.000 claims description 5
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 5
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 5
- 208000029498 hypoalphalipoproteinemia Diseases 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 208000028867 ischemia Diseases 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- JWAMAENDYWGEDT-UHFFFAOYSA-N 2-(4-chlorophenoxy)ethanethioic s-acid Chemical compound SC(=O)COC1=CC=C(Cl)C=C1 JWAMAENDYWGEDT-UHFFFAOYSA-N 0.000 claims description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 4
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 208000037487 Endotoxemia Diseases 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 206010063837 Reperfusion injury Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- OVRLABAFXJPIMU-UHFFFAOYSA-N 1-(2-ethylbutyl)-n-(2-sulfanylphenyl)cyclohexane-1-carboxamide Chemical compound C=1C=CC=C(S)C=1NC(=O)C1(CC(CC)CC)CCCCC1 OVRLABAFXJPIMU-UHFFFAOYSA-N 0.000 claims description 2
- WSDMOYWCWHLBPX-UHFFFAOYSA-N 1-(3-methylbutyl)-n-(2-sulfanylphenyl)cyclopentane-1-carboxamide Chemical compound C=1C=CC=C(S)C=1NC(=O)C1(CCC(C)C)CCCC1 WSDMOYWCWHLBPX-UHFFFAOYSA-N 0.000 claims description 2
- RPOWLQXTRJDTQA-UHFFFAOYSA-N 1-butyl-n-(2-sulfanylphenyl)cyclohexane-1-carboxamide Chemical compound C=1C=CC=C(S)C=1NC(=O)C1(CCCC)CCCCC1 RPOWLQXTRJDTQA-UHFFFAOYSA-N 0.000 claims description 2
- HNJZDNMUVSELCB-UHFFFAOYSA-N 1-ethyl-n-(2-sulfanylphenyl)cyclohexane-1-carboxamide Chemical compound C=1C=CC=C(S)C=1NC(=O)C1(CC)CCCCC1 HNJZDNMUVSELCB-UHFFFAOYSA-N 0.000 claims description 2
- BEZLZUVKRNXSDY-UHFFFAOYSA-N 1-methyl-n-(2-phenylsulfanylcarbonylsulfanylphenyl)cyclohexane-1-carboxamide Chemical compound C=1C=CC=C(SC(=O)SC=2C=CC=CC=2)C=1NC(=O)C1(C)CCCCC1 BEZLZUVKRNXSDY-UHFFFAOYSA-N 0.000 claims description 2
- YOTSORLUOLPCCV-UHFFFAOYSA-N 1-propan-2-yl-n-(2-sulfanylphenyl)cyclohexane-1-carboxamide Chemical compound C=1C=CC=C(S)C=1NC(=O)C1(C(C)C)CCCCC1 YOTSORLUOLPCCV-UHFFFAOYSA-N 0.000 claims description 2
- GIBQUYMCEXFBRU-UHFFFAOYSA-N 1-propyl-n-(2-sulfanylphenyl)cyclohexane-1-carboxamide Chemical compound C=1C=CC=C(S)C=1NC(=O)C1(CCC)CCCCC1 GIBQUYMCEXFBRU-UHFFFAOYSA-N 0.000 claims description 2
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- LRXMNFMNMFWCOJ-UHFFFAOYSA-N methyl [2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl]sulfanylformate Chemical compound COC(=O)SC1=CC=CC=C1NC(=O)C1(CCC(C)C)CCCCC1 LRXMNFMNMFWCOJ-UHFFFAOYSA-N 0.000 claims description 2
- LHNSUEDKNSIQML-UHFFFAOYSA-N n-(4,5-dichloro-2-sulfanylphenyl)-1-(3-methylbutyl)cyclopentane-1-carboxamide Chemical compound C=1C(Cl)=C(Cl)C=C(S)C=1NC(=O)C1(CCC(C)C)CCCC1 LHNSUEDKNSIQML-UHFFFAOYSA-N 0.000 claims description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 claims description 2
- AFVJGCXNVCMGBC-UHFFFAOYSA-N s-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methoxyethanethioate Chemical compound C=1C=CC=C(SC(=O)COC)C=1NC(=O)C1(CC(CC)CC)CCCCC1 AFVJGCXNVCMGBC-UHFFFAOYSA-N 0.000 claims description 2
- CCSJXVJLCREWRO-UHFFFAOYSA-N s-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] ethanethioate Chemical compound C=1C=CC=C(SC(C)=O)C=1NC(=O)C1(CC(CC)CC)CCCCC1 CCSJXVJLCREWRO-UHFFFAOYSA-N 0.000 claims description 2
- MJGXFBMXAVDVQR-UHFFFAOYSA-N s-[2-[[1-(2-methylpropyl)cyclohexanecarbonyl]amino]phenyl] 1-acetylpiperidine-4-carbothioate Chemical compound C=1C=CC=C(SC(=O)C2CCN(CC2)C(C)=O)C=1NC(=O)C1(CC(C)C)CCCCC1 MJGXFBMXAVDVQR-UHFFFAOYSA-N 0.000 claims description 2
- ZSWAVFZBRNIUBU-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]-4-(trifluoromethyl)phenyl] 2,2-dimethylpropanethioate Chemical compound C=1C(C(F)(F)F)=CC=C(SC(=O)C(C)(C)C)C=1NC(=O)C1(CCC(C)C)CCCCC1 ZSWAVFZBRNIUBU-UHFFFAOYSA-N 0.000 claims description 2
- WIDPRMXSHTWZFE-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] 2,2-dimethylpropanethioate Chemical compound C=1C=CC=C(SC(=O)C(C)(C)C)C=1NC(=O)C1(CCC(C)C)CCCCC1 WIDPRMXSHTWZFE-UHFFFAOYSA-N 0.000 claims description 2
- HYSIQIZWVLUQLT-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-acetamido-3-phenylpropanethioate Chemical compound C=1C=CC=C(SC(=O)C(CC=2C=CC=CC=2)NC(C)=O)C=1NC(=O)C1(CCC(C)C)CCCCC1 HYSIQIZWVLUQLT-UHFFFAOYSA-N 0.000 claims description 2
- CVPUOEPURYNJKD-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methoxyethanethioate Chemical compound COCC(=O)SC1=CC=CC=C1NC(=O)C1(CCC(C)C)CCCCC1 CVPUOEPURYNJKD-UHFFFAOYSA-N 0.000 claims description 2
- FRZSEBDDONUPPE-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-phenoxyethanethioate Chemical compound C=1C=CC=C(SC(=O)COC=2C=CC=CC=2)C=1NC(=O)C1(CCC(C)C)CCCCC1 FRZSEBDDONUPPE-UHFFFAOYSA-N 0.000 claims description 2
- UEQKYAQEIJRSJL-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] cyclopropanecarbothioate Chemical compound C=1C=CC=C(SC(=O)C2CC2)C=1NC(=O)C1(CCC(C)C)CCCCC1 UEQKYAQEIJRSJL-UHFFFAOYSA-N 0.000 claims description 2
- ZWIFWJMAXNUTID-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] propanethioate Chemical compound CCC(=O)SC1=CC=CC=C1NC(=O)C1(CCC(C)C)CCCCC1 ZWIFWJMAXNUTID-UHFFFAOYSA-N 0.000 claims description 2
- IUOPLRYKLPOZOU-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] pyridine-3-carbothioate Chemical compound C=1C=CC=C(SC(=O)C=2C=NC=CC=2)C=1NC(=O)C1(CCC(C)C)CCCCC1 IUOPLRYKLPOZOU-UHFFFAOYSA-N 0.000 claims description 2
- XBYRAJQIWBCYTG-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclopentanecarbonyl]amino]phenyl] ethanethioate Chemical compound C=1C=CC=C(SC(C)=O)C=1NC(=O)C1(CCC(C)C)CCCC1 XBYRAJQIWBCYTG-UHFFFAOYSA-N 0.000 claims description 2
- OLXQLAYHYKQVRD-UHFFFAOYSA-N s-[4,5-dichloro-2-[(1-pentylcyclohexanecarbonyl)amino]phenyl] 2,2-dimethylpropanethioate Chemical compound C=1C(Cl)=C(Cl)C=C(SC(=O)C(C)(C)C)C=1NC(=O)C1(CCCCC)CCCCC1 OLXQLAYHYKQVRD-UHFFFAOYSA-N 0.000 claims description 2
- ITEBOTJVVWYIQA-UHFFFAOYSA-N s-[4,5-dichloro-2-[(1-propan-2-ylcyclohexanecarbonyl)amino]phenyl] 2,2-dimethylpropanethioate Chemical compound C=1C(Cl)=C(Cl)C=C(SC(=O)C(C)(C)C)C=1NC(=O)C1(C(C)C)CCCCC1 ITEBOTJVVWYIQA-UHFFFAOYSA-N 0.000 claims description 2
- MPTSSPNHRTXQBL-UHFFFAOYSA-N s-[4,5-dichloro-2-[[1-(3-methylbutyl)cycloheptanecarbonyl]amino]phenyl] 2,2-dimethylpropanethioate Chemical compound C=1C(Cl)=C(Cl)C=C(SC(=O)C(C)(C)C)C=1NC(=O)C1(CCC(C)C)CCCCCC1 MPTSSPNHRTXQBL-UHFFFAOYSA-N 0.000 claims description 2
- BFYLHKTYMPKXHG-UHFFFAOYSA-N s-[4,5-dichloro-2-[[1-(3-methylbutyl)cyclopentanecarbonyl]amino]phenyl] 2,2-dimethylpropanethioate Chemical compound C=1C(Cl)=C(Cl)C=C(SC(=O)C(C)(C)C)C=1NC(=O)C1(CCC(C)C)CCCC1 BFYLHKTYMPKXHG-UHFFFAOYSA-N 0.000 claims description 2
- NOPRLOFLORGLJY-UHFFFAOYSA-N s-[4,5-dichloro-2-[[1-(cyclohexylmethyl)cyclohexanecarbonyl]amino]phenyl] 2,2-dimethylpropanethioate Chemical compound CC(C)(C)C(=O)SC1=CC(Cl)=C(Cl)C=C1NC(=O)C1(CC2CCCCC2)CCCCC1 NOPRLOFLORGLJY-UHFFFAOYSA-N 0.000 claims description 2
- MSFCBUDDVRTHPO-UHFFFAOYSA-N s-[4,5-dichloro-2-[[1-(cyclopropylmethyl)cyclohexanecarbonyl]amino]phenyl] 2,2-dimethylpropanethioate Chemical compound CC(C)(C)C(=O)SC1=CC(Cl)=C(Cl)C=C1NC(=O)C1(CC2CC2)CCCCC1 MSFCBUDDVRTHPO-UHFFFAOYSA-N 0.000 claims description 2
- TURBPAKUUPDMHO-UHFFFAOYSA-N s-[4-chloro-2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] 2,2-dimethylpropanethioate Chemical compound C=1C(Cl)=CC=C(SC(=O)C(C)(C)C)C=1NC(=O)C1(CCC(C)C)CCCCC1 TURBPAKUUPDMHO-UHFFFAOYSA-N 0.000 claims description 2
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 claims 2
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 claims 2
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 claims 2
- 230000004952 protein activity Effects 0.000 claims 2
- JFSITGAAFRQGKX-UHFFFAOYSA-N 1-(3-methylbutyl)-n-(3-methyl-2-sulfanylphenyl)cyclohexane-1-carboxamide Chemical compound C=1C=CC(C)=C(S)C=1NC(=O)C1(CCC(C)C)CCCCC1 JFSITGAAFRQGKX-UHFFFAOYSA-N 0.000 claims 1
- XCFKYPVNRYNNEM-UHFFFAOYSA-N 1-acetylpiperidine-4-carbothioic s-acid Chemical compound CC(=O)N1CCC(C(S)=O)CC1 XCFKYPVNRYNNEM-UHFFFAOYSA-N 0.000 claims 1
- LRWUYINHKRXNQH-UHFFFAOYSA-N 1-methyl-n-(2-sulfanylphenyl)cyclohexane-1-carboxamide Chemical compound C=1C=CC=C(S)C=1NC(=O)C1(C)CCCCC1 LRWUYINHKRXNQH-UHFFFAOYSA-N 0.000 claims 1
- KXRJJYXTXACAKT-UHFFFAOYSA-N 2-acetamido-5-amino-5-oxopentanethioic s-acid Chemical compound CC(=O)NC(C(S)=O)CCC(N)=O KXRJJYXTXACAKT-UHFFFAOYSA-N 0.000 claims 1
- UIJGNTRUPZPVNG-UHFFFAOYSA-N benzenecarbothioic s-acid Chemical compound SC(=O)C1=CC=CC=C1 UIJGNTRUPZPVNG-UHFFFAOYSA-N 0.000 claims 1
- LQFDPYJSONNAFO-UHFFFAOYSA-N cyclohexanecarbothioic s-acid Chemical compound SC(=O)C1CCCCC1 LQFDPYJSONNAFO-UHFFFAOYSA-N 0.000 claims 1
- GHSLUZCHSFWKRE-UHFFFAOYSA-N n-(4,5-dichloro-2-sulfanylphenyl)-1-(3-methylbutyl)cyclohexane-1-carboxamide Chemical compound C=1C(Cl)=C(Cl)C=C(S)C=1NC(=O)C1(CCC(C)C)CCCCC1 GHSLUZCHSFWKRE-UHFFFAOYSA-N 0.000 claims 1
- SSAIZJDBBXDECD-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-chloroethanethioate Chemical compound C=1C=CC=C(SC(=O)CCl)C=1NC(=O)C1(CCC(C)C)CCCCC1 SSAIZJDBBXDECD-UHFFFAOYSA-N 0.000 claims 1
- MXLMXGUKFHEMNV-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-hydroxy-2-methylpropanethioate Chemical compound C=1C=CC=C(SC(=O)C(C)(C)O)C=1NC(=O)C1(CCC(C)C)CCCCC1 MXLMXGUKFHEMNV-UHFFFAOYSA-N 0.000 claims 1
- XHVJBTXLUDEYRF-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CCC(C)C)CCCCC1 XHVJBTXLUDEYRF-UHFFFAOYSA-N 0.000 claims 1
- HWBRDPQUXXEYBF-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] n-phenylcarbamothioate Chemical compound C=1C=CC=C(SC(=O)NC=2C=CC=CC=2)C=1NC(=O)C1(CCC(C)C)CCCCC1 HWBRDPQUXXEYBF-UHFFFAOYSA-N 0.000 claims 1
- QRUWEPAFXQSBDS-UHFFFAOYSA-N s-[4-fluoro-2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] 2,2-dimethylpropanethioate Chemical compound C=1C(F)=CC=C(SC(=O)C(C)(C)C)C=1NC(=O)C1(CCC(C)C)CCCCC1 QRUWEPAFXQSBDS-UHFFFAOYSA-N 0.000 claims 1
- FEENFRZHDJHJGY-UHFFFAOYSA-N s-[5-fluoro-2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] 2,2-dimethylpropanethioate Chemical compound C=1C=C(F)C=C(SC(=O)C(C)(C)C)C=1NC(=O)C1(CCC(C)C)CCCCC1 FEENFRZHDJHJGY-UHFFFAOYSA-N 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 description 33
- 108010023302 HDL Cholesterol Proteins 0.000 description 28
- 230000036470 plasma concentration Effects 0.000 description 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
- 239000000902 placebo Substances 0.000 description 17
- 229940068196 placebo Drugs 0.000 description 17
- 239000003814 drug Substances 0.000 description 16
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 15
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 15
- 125000003342 alkenyl group Chemical group 0.000 description 15
- 239000000460 chlorine Substances 0.000 description 15
- 229910052801 chlorine Inorganic materials 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 229910052731 fluorine Inorganic materials 0.000 description 15
- 239000011737 fluorine Substances 0.000 description 15
- 230000003247 decreasing effect Effects 0.000 description 14
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- 235000021152 breakfast Nutrition 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 229940125904 compound 1 Drugs 0.000 description 10
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 10
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 10
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 9
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 8
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 8
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 7
- 108010010234 HDL Lipoproteins Proteins 0.000 description 7
- 102000015779 HDL Lipoproteins Human genes 0.000 description 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 6
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- 229940033134 talc Drugs 0.000 description 6
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 5
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 230000009246 food effect Effects 0.000 description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 4
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 239000011812 mixed powder Substances 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 125000005936 piperidyl group Chemical group 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 125000006065 1,3-dimethyl-2-butenyl group Chemical group 0.000 description 2
- 125000006025 1-methyl-1-butenyl group Chemical group 0.000 description 2
- 125000006048 1-methyl-2-pentenyl group Chemical group 0.000 description 2
- 125000006021 1-methyl-2-propenyl group Chemical group 0.000 description 2
- 125000006023 1-pentenyl group Chemical group 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 238000012369 In process control Methods 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000010965 in-process control Methods 0.000 description 2
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- INKBUBAEIMNSIG-UHFFFAOYSA-N 1-(2-methylpropyl)-n-(2-sulfanylphenyl)cyclohexane-1-carboxamide Chemical compound C=1C=CC=C(S)C=1NC(=O)C1(CC(C)C)CCCCC1 INKBUBAEIMNSIG-UHFFFAOYSA-N 0.000 description 1
- OBWOWYBSZTURFB-UHFFFAOYSA-N 1-(3-methylbutyl)-n-(2-sulfanylphenyl)cyclohexane-1-carboxamide Chemical compound C=1C=CC=C(S)C=1NC(=O)C1(CCC(C)C)CCCCC1 OBWOWYBSZTURFB-UHFFFAOYSA-N 0.000 description 1
- QSHCOFDJVJBWJU-UHFFFAOYSA-N 1-(3-methylbutyl)-n-(4-methyl-2-sulfanylphenyl)cyclohexane-1-carboxamide Chemical compound C=1C=C(C)C=C(S)C=1NC(=O)C1(CCC(C)C)CCCCC1 QSHCOFDJVJBWJU-UHFFFAOYSA-N 0.000 description 1
- ZUBAYESAZFWZPL-UHFFFAOYSA-N 1-(3-methylbutyl)-n-(5-methyl-2-sulfanylphenyl)cyclohexane-1-carboxamide Chemical compound C=1C(C)=CC=C(S)C=1NC(=O)C1(CCC(C)C)CCCCC1 ZUBAYESAZFWZPL-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006030 1-methyl-3-butenyl group Chemical group 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- IRYMZPFJICXSLB-UHFFFAOYSA-N 2-chloroethanethioic s-acid Chemical compound SC(=O)CCl IRYMZPFJICXSLB-UHFFFAOYSA-N 0.000 description 1
- MYVQIUBQBFLOST-UHFFFAOYSA-N 2-hydroxy-2-methylpropanethioic s-acid Chemical compound CC(C)(O)C(O)=S MYVQIUBQBFLOST-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004924 2-naphthylethyl group Chemical group C1=C(C=CC2=CC=CC=C12)CC* 0.000 description 1
- 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 description 1
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 125000005303 dithiazolyl group Chemical group S1SNC(=C1)* 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000003745 glyceroyl group Chemical group C(C(O)CO)(=O)* 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- BMBJSXKEXRFGAV-UHFFFAOYSA-N phenylcarbamothioic s-acid Chemical compound SC(=O)NC1=CC=CC=C1 BMBJSXKEXRFGAV-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- KOODSCBKXPPKHE-UHFFFAOYSA-N propanethioic s-acid Chemical compound CCC(S)=O KOODSCBKXPPKHE-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- WBCRBXAFIQXPJQ-UHFFFAOYSA-N s-[2-[(1-methylcyclohexanecarbonyl)amino]phenyl] 2,2-dimethylpropanethioate Chemical compound CC(C)(C)C(=O)SC1=CC=CC=C1NC(=O)C1(C)CCCCC1 WBCRBXAFIQXPJQ-UHFFFAOYSA-N 0.000 description 1
- CUFAKTNZJHSRMF-UHFFFAOYSA-N s-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 1-acetylpiperidine-4-carbothioate Chemical compound C=1C=CC=C(SC(=O)C2CCN(CC2)C(C)=O)C=1NC(=O)C1(CC(CC)CC)CCCCC1 CUFAKTNZJHSRMF-UHFFFAOYSA-N 0.000 description 1
- AVHJWJNTHBRPPL-UHFFFAOYSA-N s-[2-[[1-(2-methylpropyl)cyclohexanecarbonyl]amino]phenyl] 2-(4-chlorophenoxy)ethanethioate Chemical compound C=1C=CC=C(SC(=O)COC=2C=CC(Cl)=CC=2)C=1NC(=O)C1(CC(C)C)CCCCC1 AVHJWJNTHBRPPL-UHFFFAOYSA-N 0.000 description 1
- ZKLYDYIGXBYRKG-UHFFFAOYSA-N s-[2-[[1-(2-methylpropyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(C)C)CCCCC1 ZKLYDYIGXBYRKG-UHFFFAOYSA-N 0.000 description 1
- LJSAHYCOQKCCQZ-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]-4-nitrophenyl] 2,2-dimethylpropanethioate Chemical compound C=1C([N+]([O-])=O)=CC=C(SC(=O)C(C)(C)C)C=1NC(=O)C1(CCC(C)C)CCCCC1 LJSAHYCOQKCCQZ-UHFFFAOYSA-N 0.000 description 1
- FXIULSQKMBPEOI-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-(4-chlorophenoxy)ethanethioate Chemical compound C=1C=CC=C(SC(=O)COC=2C=CC(Cl)=CC=2)C=1NC(=O)C1(CCC(C)C)CCCCC1 FXIULSQKMBPEOI-UHFFFAOYSA-N 0.000 description 1
- OTMSDUWIKWKOJA-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-acetamido-5-amino-5-oxopentanethioate Chemical compound C=1C=CC=C(SC(=O)C(CCC(N)=O)NC(C)=O)C=1NC(=O)C1(CCC(C)C)CCCCC1 OTMSDUWIKWKOJA-UHFFFAOYSA-N 0.000 description 1
- PAUVZWIHHQXRET-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] benzenecarbothioate Chemical compound C=1C=CC=C(SC(=O)C=2C=CC=CC=2)C=1NC(=O)C1(CCC(C)C)CCCCC1 PAUVZWIHHQXRET-UHFFFAOYSA-N 0.000 description 1
- OYMZRBRXYBINJS-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] cyclohexanecarbothioate Chemical compound C=1C=CC=C(SC(=O)C2CCCCC2)C=1NC(=O)C1(CCC(C)C)CCCCC1 OYMZRBRXYBINJS-UHFFFAOYSA-N 0.000 description 1
- JDXPRSNPJGKLDY-UHFFFAOYSA-N s-[2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] ethanethioate Chemical compound C=1C=CC=C(SC(C)=O)C=1NC(=O)C1(CCC(C)C)CCCCC1 JDXPRSNPJGKLDY-UHFFFAOYSA-N 0.000 description 1
- JFCOHMGXJCIKPZ-UHFFFAOYSA-N s-[4,5-dichloro-2-[(1-cyclopropylcyclohexanecarbonyl)amino]phenyl] 2,2-dimethylpropanethioate Chemical compound CC(C)(C)C(=O)SC1=CC(Cl)=C(Cl)C=C1NC(=O)C1(C2CC2)CCCCC1 JFCOHMGXJCIKPZ-UHFFFAOYSA-N 0.000 description 1
- LRLVDOHJDUBITP-UHFFFAOYSA-N s-[4,5-dichloro-2-[[1-(3-methylbutyl)cyclobutanecarbonyl]amino]phenyl] 2,2-dimethylpropanethioate Chemical compound C=1C(Cl)=C(Cl)C=C(SC(=O)C(C)(C)C)C=1NC(=O)C1(CCC(C)C)CCC1 LRLVDOHJDUBITP-UHFFFAOYSA-N 0.000 description 1
- LSJSNHMUBPMISY-UHFFFAOYSA-N s-[4,5-dichloro-2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] 2,2-dimethylpropanethioate Chemical compound C=1C(Cl)=C(Cl)C=C(SC(=O)C(C)(C)C)C=1NC(=O)C1(CCC(C)C)CCCCC1 LSJSNHMUBPMISY-UHFFFAOYSA-N 0.000 description 1
- PPLIUJAXWQFCOC-UHFFFAOYSA-N s-[5-chloro-2-[[1-(3-methylbutyl)cyclohexanecarbonyl]amino]phenyl] 2,2-dimethylpropanethioate Chemical compound C=1C=C(Cl)C=C(SC(=O)C(C)(C)C)C=1NC(=O)C1(CCC(C)C)CCCCC1 PPLIUJAXWQFCOC-UHFFFAOYSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005307 thiatriazolyl group Chemical group S1N=NN=C1* 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Description
Co. 1 : DESCRIPTION
PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS
This invention pertains to compositions and methods for the treatment or prophylaxis of cardiovascular disorders comprising CETP inhibitors.
Hyperlipidemic conditions associated with elevated concentrations of total cholesterol and low-density lipoprotein (LDL) cholesterol are major risk factors for . coronary heart disease, and atherosclerosis in particular. Additionally, numerous studies have demonstrated that a low plasma concentration of high-density lipoprotein (HDL) chelesterol is a powerful risk factor for the development of atherosclerosis.
Cholesteryl ester transfer protein (CET P) is a plasma protein that facilitates the “movement of cholesteryl esters and triglycerides between various lipoproteins in the blood.
The movement of cholesteryl ester from HDL to LDL by CETP has the effect of lowering
HDL cholesterol and increasing LDL cholesterol. Inhibition of CETP activity by CETP inhibitors has been shown to effectively modify plasmid HDL/LDL ratios by elevating plasma HDL cholesterol and lowering plasma LDL cholesterol. -
To be effective, CETP inhibitors must be absorbed into the blood. Oral dosing of CETP inhibitors is preferred because to be effective such CETP inhibitors must be taken on a regular basis, such as daily. CETP inhibitors, particularly those that have high binding activity, are generally hydrophobic, have extremely low aqueous solubility, and have low. oral bioavailability when dosed gonventionally. Such compounds have generally proven to be difficult to formulate for oral administration such that high bioavailabilities are achieved.
International Patent Application WO 02/11710 recognizes this problem of low bioavailability and atteinpts to solve such a problem by formulating a composition comprising a solid dispersion of a CETP inhibitor in an amorphous form and a water- soluble polymer that increases the concentration of the CETP inhibitor in the environment of use.. However, as many CETP inhibitors are in crystalline form, there is an ongoing need for improved compositions of crystalline CETP inhibitors.
Therefore, there remains a need for pharmaceutical compositions comprising
CETP inhibitors in crystalline form that result in increased bioavailability of the CETP, inhibitors in the environment of use. The invention provides such a pharmaceutical composition and methods of treating cardiovascular disorders using the pharmaceutical
AMENDED SHEET: 13 JULY 2006 compositions. These and other advantages of the invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.
S The invention provides a pharmaceutical composition comprising a cholesteryl ester transfer protein inhibitor and a water-insoluble concentration-enhancing additive, such as crospovidone.
The invention also provides a method for treating or preventing a cardiovascular disorder in a mammal by administering to a mammal in need of such treatment a therapeutically effective amount of the pharmaceutical composition provided by the invention.
Figure 1 is a linear plot of the geometric mean plasma concentrations (ng/mL) of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonylJamino)phenyl] 2- methylpropanethioate over 36 hours in Caucasian male patients, who were orally administered 900 mg of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyljamino)phenyl] 2- methylpropanethioate with food or without food.
Figure 2 is a semi-logarithmic plot of the geometric mean plasma concentrations (ug/ml) of the active form of S-[2-([{1-(2-ethylbutyl)cyclohexyl]carbonyl]Jamino)phenyl] 2-methylpropanethioate over 36 hours in Caucasian male patients, who were orally administered 900 mg of S-[2-([[1-(2-ethylbutyl)cyclohe:yl]carbonyljamino)phenyl] 2- methylpropanethioate with food or without food.
Figure 3 is plot of the mean changes from baseline (pre-dose) in CETP activity over 24 hours in Caucasian male patients, who were orally administered 900 mg of S-[2- ([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate with food or without food.
Figure 4 is a plot of mean CETP activities and mean plasma concentrations of the active form of S-[2-([[1 -(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2- methylpropanethioate over 24 hours in Caucasian male patients following the oral administration of 900 mg of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2- methylpropanethioate with food.
Figure 5 is a plot of mean CETP activities and mean plasma concentrations of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2- methylpropanethioate over 24 hours in Caucasian male patients following the oral administration of 900 mg of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2- methylpropanethioate without food.
The invention provides compositions of at least one CETP inhibitor and at least one water-insoluble concentration-enhancing additive, wherein the additive desirably increases the bioavailability of the CETP inhibitor, or the active form thereof, relative to the administration of the CETP inhibitor in the absence of the additive. : The CETP inhibitor signifies any compound that inhibits CETP or forms an active form that inhibits CETP. Any suitable CETP inhibitor can be used in the context of the invention, such as those described in U.S. Patents 6,140,342, 6,140,343, 6,147,089, 6,147,090, 6,197,786; and 6,426,365; European Patent Publication Numbers EP 796846 Al and EP 818448 Al; and International Patent Publication Numbers WO 98/04528, WO 98/35937, WO 99/14174, WO 99/14204, WO 99/14215, WO 99/41237, and WO 02/11710.
Preferably, the CETP inhibitor is a compound of Formula I:
Formula I 0) : I
R NH
X S—7Z
Xo Xs or a prodrug compound, pharmaceutically acteptable salt, enantiomer, stereoisomer, hydrate, or solvate of the compound of Formula I. In Formula I, R represents a substituted or unsubstituted Cs.jo cycloalkyl group or a substituted or unsubstituted Cs.s cycloalkenyl group. Each of Xj, X», Xs, and X, may be the same or different and represents one or more of the following: a hydrogen atom; a halogen atom; a Ci alkyl group; a halo-C 4 alkyl group; a Cy 4 alkoxy group; a Cyano group; a nitro group; an acyl group; or an aryl group. Z represents a hydrogen atom, —YR; (wherein Y represents —CO— or —CS-—, and R; represents asubstituted or unsubstituted straight chain or branched C).1o alkyl group; a C4 alkoxy group; a C4 alkylthio group; a substituted or unsubstituted amino group; a substituted or unsubstituted ureido group; a substituted or unsubstituted Cs.1¢ cycloalkyl group; a substituted or unsubstituted Cs; cycloalkyl Cy.p0 alkyl group: a substituted or unsubstituted aryl group; a substituted or unsubstituted aralkyl group; a substituted or unsubstituted arylalkenyl group; a substituted ot unsubstituted arylthio group; a substituted or unsubstituted 5- or 6-membered heterocyclic group having 1-3 nitrogen, oxygen, or sulfur atoms; or a substituted or unsubstituted 5- or 6-membered heteroarylaklyl group), or —S—R;
AMENDED SHEET: 13 JULY 2006
(wherein R; represents a substituted or unsubstituted C,.4 alkyl group or a substituted or unsubstituted aryl group).
The term “straight chain or branched Ci.0 alkyl group” used herein means an alkyl group having 1-10 carbon atoms which may be straight or branched. Specific examples thereof include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert- butyl, pentyl, isopentyl, neopentyl, tert-pentyl, 1-ethylbutyl, 2-ethylbutyl, 1-propylbutyl, 1,1-dimethylbutyl, 1-isobutyl-3-methylbutyl, 1-ethylpentyl, 1 -propylpentyl, 1- isobutylpentyl, 2-ethylpentyl, 2-isopropylpentyl, 2-tert-butylpentyl, 3-ethylpentyl, 3- isopropylpentyl, 4-methylpentyl, 1,4-dimethylpentyl, 2,4-dimethylpentyl, 1-ethyl-4- methylpentyl, hexyl, 1-ethylhexyl, 1-propylhexyl, 2-ethylhexyl, 2-isopropylhexyl, 2-tert- butylhexyl, 3-ethythexyl, 3-isopropylhexyl, 3-tert-butylhexyl, 4-ethylhexyl, S-methylhexyl, heptyl, 1-ethylheptyl, 1-isopropylheptyl, 2-ethylheptyl, 2-isopropytheptyl, 3-propylheptyl, 4-propylheptyl, S-ethylheptyl, 6-methylheptyl, octyl, 1-ethyloctyl, 2-ethyloctyl, nonyl, 1- methylnonyl, 2-methylnonyl, decyl, and the like groups. A straight chain or branched alkyl group having 1-8 carbon atoms is preferred.
The term “C1.4 lower alkyl group” used herein means an alkyl group having 1-4 carbon atoms, and specifically includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, and the like groups.
The term “straight chain or branched Cs. alkenyl group” means an alkenyl group having 2-10 carbon atoms with at least one or more double bonds, which may be straight or branched. Specific examples thereof include allyl, vinyl, isopropenyl, 1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-methyl-1-butenyl, crotyl, 1-methyl-3-butenyl, 3-methyl-2-butenyl, 1,3-dimethyl-2-butenyl, 1-pentenyl, 1-methyl-2-pentenyl, 1-ethyl-3- pentenyl, 4-pentenyl, 1,3-pentadienyl, 2,4-pentadienyl, 1-hexenyl, 1-methyl-2-hexenyl, 3- hexenyl, 4-hexenyl, 1-butyl-5-hexenyl, 1,3-hexadienyl, 2,4-hexadienyl, 1-heptenyl, 2- heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1,3-heptadienyl, 2,4-heptadienyl, 1-octenyl, 2-octenyl, 3-octenyl, 4-octenyl, S-octenyl, 6-octenyl, 7-octenyl, 1-nonenyl, 2- nonenyl, 3-nonenyl, 4-nonenyl, 5-nonenyl, 6-nonenyl, 7-nonenyl, 8-nonenyl, 9-decenyl, and the like groups. An alkenyl group having 2-8 carbon atoms, which may be straight or branched, is preferred.
The term “halogen atom” means fluorine, chlorine, and bromine atoms.
The term “halo-C,.4 alkyl group” means the above-described C4 lower alkyl group substituted with 1-3 halogens, which may be the same or different. Specific examples thereof include fluoromethyl, chloromethyl, bromomethyl, difluoromethyl, dichloromethyl, trifluoromethyl, trichloromethyl, chloroethyl, difluoroethyl, trifluoroethyl, pentachloroethyl, bromopropyl, dichloropropyl, trifluorobutyl, and the like groups.
Trifluoromethyl and chloroethyl are preferred.
The term “C4 lower alkoxy group” means the alkoxy group containing the Ci.4 lower alkyl group as described above. Examples thereof include methoxy, ethoXy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, and the like groups.
The term “C4 lower alkylthio group” means the alkylthio group containing the 5 C.lower alkyl group as described above. Examples thereof include methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, and the like groups.
The term “Cs.yo cycloalkyl group” means a cycloalkyl group having 3-10 carbon atoms, which may be monocyclic or polycyclic. Examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, octahydroindenyl, decahydronaphthyl, bicyclo[2.2.1]heptyl, adamantyl, and the like groups. Preferred are those having 5-7 carbon atoms, including cyclopentyl, cyclohexyl, and cycloheptyl.
The term “Cs.g cycloalkenyl group” means a cycloalkenyl group having 5-8 carbon atoms with one or more double bonds on the ring. Examples thereof include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclopentadienyl, cyclohexadienyl, cycloheptadienyl, cyclooctadienyl, and the like groups. Preferred are those with 5-7 carbon atoms, including cyclopentenyl, cyclohexenyl, and cycloheptenyl.
The term “Cj.10 cycloalkyl Cj.10 alkyl group” means the above-described straight chain or branched Cy. alkyl group substituted with the above-described Cs.io cycloalkyl group. Specific examples thereof include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexyl cyclopentylmethyl, dicyclohexylmethyl, 1-cyclopentylethyl, 1-cyclohexylethyl, 2-cyclopropylethyl, 2-cyclopentylethyl, 2-cyclohexylethyl, 2- cycloheptylethyl, 1-cyclohexyl-1-methylethyl, 1-cyclohexylpropyl, 2-cyclopentylpropyl, 3- cyclobutylpropyl, 3-cyclopentylpropyl, 3-cyclohexylpropyl, 3-cycloheptylpropyl, 1- cyclopropyl-1-methylpropyl, 1-cyclohexyl-2-methylpropyl, 1-cyclopentylbutyi, 1- cyclohexylbutyl, 3-cyclohexylbutyl, 4-cyclopropylbutyl, 4-cyclobutylbutyl, 4- cyclopentylbutyl, 1-cyclohexyl-1-methylbutyl, 1-cyclopentyl-2-ethylbutyl, 1-cyclohexyl-3- methylbutyl, 1-cyclopentylpentyl, 1-cyclohexylpentyl, 1-cyclohexylmethylpentyl, 2- cyclohexylpentyl, 2-cyclohexylmethylpentyl, 3-cyclopentylpentyl, 1-cyclohexyl-4- methylpentyl, 5-cyclopentylpentyl, 1-cyclopentylhexyl, 1-cyclohexylhexyl, 1- cyclopentylmethylhexyl, 2-cyclopentylhexyl, 2-cyclopropylethylhexyl, 3-cyclopentylhexyl, 1-cyclohexylheptyl, 1-cyclopentyl-1-methylheptyl, 1-cyclohexyl-1,6-dimethylheptyl, 1- cycloheptyloctyl, 2-cyclopentyloctyl, 3-cyclohexyloctyl, 2-cyclopentylmethyloctyl, 1- cyclopentylnonyl, 1-cyclohexylnonyl, 3-cyclopropylnonyl, 1-cyclopentyldecyl, 1- cyclohexylundecyl, 1-cyclopentyltridecyl, 2-cyclohexyltridecyl, and the like groups.
The “aryl group” includes phenyl, naphthyl, anthryl, phenanthryl, biphenyl, and the like groups. Phenyl, naphthyl, and biphenyl groups are preferred.
The “aralkyl group” means the above-described C;.4 lower alkyl group substituted with one or more aryl groups as described above. Examples thereof include benzyl, benzhydryl, trityl, phenethyl, 3-phenylpropyl, 2-phenylpropyl, 4-phenylbutyl, naphthylmethyl, 2-naphthylethyl, 4-biphenylmethyl, 3-(4-biphenyl) propyl, and the like 5S groups.
The “arylalkenyl group” means an alkenyl group having 2-4 carbon atoms substituted with the above-described aryl group. Examples thereof include 2-phenylvinyl, 3-phenyl-2-propenyl, 3-phenyl-2-methyl-2-propenyl, 4-phenyl-3-butenyl, 2-(1- naphthyl)vinyl, 2-(2-naphthyl)vinyl, 2-(4-biphenyl)vinyl, and the like groups.
The “arylthio group” means an arylthio group containing the above-described aryl group and specifically include phenylthio, naphthylthio, and the like groups.
The “heterocyclic group” means a 5- and 6-membered aromatic or non-aromatic heterocyclic ring containing at least one or more, specifically 1-4, preferably 1-3, hetero atoms selected from nitrogen, oxygen, and sulfur atoms. Specific examples thereof include aromatic heterocyclic rings such as thiatriazolyl, tetrazolyl, dithiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, oxazolyl, pyrazolyl, pyrrolyl, furyl, thienyl, tetrazinyl, triazinyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridyl, or the like groups and non-aromatic heterocyclic rings such as dioxoranyl, pyrrolidinyl, tetrahydrofuryl, tetrahydrothienyl, dithiadiazinyl, thiadiazinyl, morpholine, morpholinyl, oxazinyl, thiazinyl, piperazinyl, piperidyl, piperidino, pyranyl, thiopyranyl, or the like groups. Preferable groups are aromatic heterocyclic (heteroaryl) groups including furyl, thienyl, pyrrolyl, pyridyl, and the like and non-aromatic heterocyclic groups containing at least one nitrogen atom, including pyrrolidinyl, tetrahydrofuryl, piperazinyl, piperidyl, piperidino, and the like groups.
The “heteroarylalkyl group” means the above-described C1.4 lower alkyl group substituted with the above-described 5- or 6-membered aromatic heterocyclic (heteroaryl) group and specifically include 2-thienylmethyl, 2-furylmethyl, 2-pyridylmethyl, 3- pyridylmethyl, 2-thienyl-2-ethyl, 3-furyl-1-ethyl, 2-pyridyl-3-propyl, and the like groups.
The “acyl group” specifically includes formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, acryloyl, propioloyl, metacryloyl, crotonoyl, benzoyl, naphthoyl, toluoyl, hydroatropoyl, atropoyl, cinnamoyl. furoyl, thenoyl, nicotinoyl, isonicotinoyl, glucoloyl, lactoyl, glyceroyl, tropoyl, benzyloyl, salicyloyl, anisoyl, vaniloyl, veratoroyl, piperoniroyl, protocatechoyl, galloyl, cyclopentanecarbonyl, cyclohexanecarbonyl, cycloheptanecarbonyl, 1-methyl cyclohexanecarbonyl, 1- isopentylcyclopentanecarbonyl, 1-isopentyl cyclohexanecarbonyl, tert-butoxycarbonyl, methoxycarbonyl, ethoxycarbonyl, 2-(1- isopentylcyclohexanecarbonylamino)phenylthiocarbonyl, and the like groups. Preferred are acetyl, tert-butoxycarbonyl, benzoyl, 1-methylcyclohexanecarbonyl, 1-
isopentylcyclopentanecarbonyl, I-isopentylcyclohexanecarbonyl, and 2-(1- isopentylcyclohexanecarbonylamino)phenylthiocarbonyl.
The term “substituted or unsubstituted” of the “substituted or unsubstituted Cs. cycloalkyl group,” the “substituted or unsubstituted Cs.g cycloalkenyl group,” and the “substituted or unsubstituted Cs.10 cycloalkyl Cy.ip alkyl group” described for R, R, and the like means that the group may be substituted with 1-4 substituents which may be the same or different and any position may be arbitrarily substituted without any limitation. Specific examples of these groups are the above-described straight chain or branched Cj.) alkyl group; the above-described straight chain or branched Cg alkenyl group; the above- described Cs cycloalkyl group; the above-described Cj. cycloalkenyl group; the above- described Cayo cycloalkyl Cy. alkyl group; the above-described aryl group; an amino group; a Cy4 lower allylamino group such as methylamino, ethylamino, or the like groups; an acylamino group such as acetylamino, propionylamino, benzylamino, or the like groups; an 0xo group; the above-described aralkyl group; the above-described arylalkenyl group, and the like.
The above substituents are recommended as substituents for R. Among these, preferred for R, are the above-described straight chain or branched C0 alkyl group, the above-described Cs.19 cycloalkyl group, the above-described Cs. cycloalkenyl group, the above-describzd aryl group, and the above-described amino group.
The term “substituted or unsubstituted” of the “substituted or unsubstituted aryl group,” the “5-.or 6-membered heterocyclic group containing 1-3 nitrogen, oxygen, or sulfur atoms,” the “substituted or unsubstituted aralkyl group,” the “substituted or unsubstituted arylalkenyl group,” the “substituted or unsubstituted arylthio group,” and the “substituted or unsubstituted 5- or 6-membered heteroarylalkyl group” described with respect to R, Ry, and the like means that the groups may be substituted with 1-4, preferably 1-3, substituents which may be the same or different and any position may be arbitrarily substituted without particular restriction. Examples of these groups include the above- described straight chain or branched C,.jo ally! group, preferably a straight chain or branched Cys alkyl group; the above-described straight chain or branched Cs.1o alkenyl group, preferably a straight chain or branched Cs. alkenyl group; the above-described halogen atom; a nitro group; the above-described amino group that may be substituted with the above-described Cy. lower alkyl group or the above-described acyl group; a hydroxyl group; the above-described Ci lower alkoxy group; the above-described Cy lower alkylthio group; the above-described halo-C; 4 lower allyl group; the above-described acyl group; an oxo group, and the like.
AMENDED SHEET: 13 JULY 2006 !
The above substituents are recommended as substituents mainly for Ry. Among these, preferred for R the above-described straight chain or branched C,.¢ alkyl group, the above-described halogen atom, and a nitro group.
The “substituted or unsubstituted” of the “substituted or unsubstituted straight chain or branched C.1o alkyl group” described for R; and the like means that the group may be substituted with 1-3 substituents which may be the same or different and any position may be arbitrarily substituted without particular restriction. Examples of these groups are the above-described Cj. lower alkoxy group; the above-described C;.4 lower alkyl group, the above-described amino group that may be substituted with an acyl or hydroxyl group; the above-described lower Cy. alkylthio group; a carbamoyl group; a hydroxyl group; the above-described halogen atom; the above-described acyloxy group containing an acyl group; a carboxyl group; the above-described acyl group; the above-described aryloxy group containing an aryl group that may be substituted; and the like.
The “substituted or unsubstituted” of the “Cj.4 lower alkyl group” described with respect to R; and the like means that the group may be substituted with 1-3 substituents which may be the same or different and any position may be arbitrarily substituted without particular restriction. Examples of the group include the above-described C4 lower alkoxy group; the above-described amino group that may be substituted with the above-described
C1. lower allcyl group or the above-described acyl group; the above-described C).q lower alkylthio group; a carbamoyl group; a hydroxyl group; a carboxyl group; the above- described acyl group; the above-described heterocyclic group (particularly aromatic heterocyclic groups such as thienyl or non-aromatic heterocyclic group such as tetrahydrofuryl); and the like.
The term “substituted or unsubstituted” of the “substituted or unsubstituted amino group” and the “substituted or unsubstituted ureido group” described with respect to
R, means that the groups may be substituted with one or more, preferably 1-2, substituents which may be the same or different and any position may be arbitrarily substituted without particular restriction. Examples of these groups are the above-described C;4 lower alkyl group; a hydroxyl group; the above-described acyl group; the above-described aryl group which may be substituted with the above-described Ci. lower alkoxy group; and the like.
More specifically, preferred as the “straight chain or branched C,.10 alkyl group” for R are methyl, ethyl, isopropyl, butyl, isobutyl, tert-butyl, heptyl, 1-propylbutyl, and 1- isobutyl-3-methylbutyl.
The “straight chain or branched C,.;o alkenyl group” referred to as R are preferably allyl, vinyl, isopropenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-methyl-1- butenyl, crotyl, 1,3-dimethyl-2-butenyl, 1-pentenyl, and 1-methyl-2-pentenyl.
The “halo-C; 4 lower alkyl group” for R means a Cy.4 lower alkyl group, particularly preferably a methyl group, substituted with the above-described halogen atom, particularly preferably fluorine and chlorine, with being a trifluoromethyl group preferred.
The “substituted or unsubstituted Cs.1o cycloalkyl group” for R means a Cs.10 cycloalkyl group (particularly preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, octahydroindenyl, decahydronaphthyl, adamantyl, and bicyclo[2.2.1Theptyl) that may be substituted with 1-4 substituents selected from the above-described straight chain or branched Co alkyl group (particularly preferably a Cs alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, 2,2- dimethylpropyl, 4-methylpentyl, 2-ethylbutyl, or the like), the above-described straight chain or branched C,.;o alkenyl group (particularly preferably a C,.g alkenyl group such as 1- methylvinyl, 2-methylvinyl, 3-methyl-3-propenyl, or the like), the above-described Cs.1o cycloalkyl group (particularly preferably a Cs.7 cycloalkyl group such as cyclopropyl, cyclopentyl, cyclohexyl, or the like), the above-described Cs.g cycloalkenyl group (particularly preferably a Cs.c cycloalkenyl group such as cyclopentenyl, cyclohexenyl, or the like), the above-described C.j cycloalkyl C.jo alkyl group (particularly preferably a Cs. s cycloalkyl C4 alkyl group such as cyclopropylmethyl, 2-cyclopropylethyl, 2- cyclopentylethyl, cyclohexylmethyl, 2-cyclohexylethyl, or the like), the above-described aryl group (particularly preferably a phenyl group), an oxo group, the above described aralkyl group (particularly preferably a phenyl C;.4 lower alkyl group such as benzyl, phenethyl, or the like), and the above-described arylalkenyl group (particularly preferably a 2-phenylvinyl group). Preferable examples thereof include 2,2,3,3-tetramethylcyclopropyl, 1-isopentylcyclobutyl, 1-isopropylcyclopentyl, 1-isobutylcyclopentyl, 1- isopentylcyclopentyl, 1-cyclohexylmethylcyclopentyl, cyclohexyl, 1-methylcyclohexyl, 1- ethylcyclohexyl, 1-propylcyclohexyl, 1-isopropylcyclohexyl, 1-butylcyclohexyl, 1- isobutylcyclohexyl, 1-pentylcyclohexyl, 1-isopentylcyclohexyl, 1-(2,2- dimethylpropyl)cyclohexyl, 1-(4-methylpentyl)cyclohexyl, 1-(2-ethylbutyl) cyclohexyl, 4- tert-butyl-1-isopentylcyclohexyl, 1-cyclopropylcyclohexyl, 1-bicyclohexyl, 1- phenylcyclohexyl, 1-cyclopropylmethylcyclohexyl, 1-cyclohexylmethylcyclohexyl, 1-(2- cyclopropylethyl) cyclohexyl, 1-(2-cyclopentylethyl)cyclohexyl, 1-(2- cyclohexylethyl)cyclohexyl, 4-methylcyclohexyl, 4-propylcyclohexyl, 4- isopropylcyclohexyl, 4-tert-butylcyclohexyl, 4-pentylcyclohexyl, 4-bicyclohexyl, 1- isopentylcycloheptyl, 3a-octahydroindenyl, 4a-decahydronaphthyl, 1-adamantyl, and 7,7- dimethyl-1-(2-0x0)-bicyclo[2.2.1]heptyl. The site of substitution is not specifically limited, but particularly preferably at position 1. Any substitution group as described above may be used, but the straight chain or branched Cj.1¢ alkyl group is particularly preferred.
A particularly preferable example of the substituted C;_jo cycloalkyl! group is a 1- substituted-Cj.0 cycloalkyl group. The “1-substituted-Cs.jo cycloalkyl group” means a cycloalkyl group (for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, preferably a Cs.; cycloalkyl group, particularly preferably a cyclohexyl group) that is substituted at position 1 with substituents selected from the above-described straight chain or branched C).jp alkyl group (particularly preferably a Cys alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, 2,2-dimethylpropyl, 4- methylpentyl, or 2-ethylbutyl), the above-described straight chain or branched Cs. alkenyl group (particularly preferably a Ca. alkenyl group such as 1-methylvinyl, 2-methylvinyl, or 3-methyl-3-propenyl), the above-described Cs.o cycloalkyl (particularly preferably a Cs. cycloalkyl group such as cyclopropyl, cyclopentyl, or cyclohexyl), the above-described Cs.g cycloalkenyl group (particularly preferably a Cs.s cycloalkenyl group such as cyclopentenyl or cyclohexenyl), the above-described Cs.jg cycloalkyl Cy.jo alkyl group (particularly preferably a Cs.7 cycloalkyl C4 lower alkyl group such as cyclopropylmethyl, 2- cyclopropylethyl, 2-cyclopentylethyl, cyclohexylmethyl, or 2-cyclohexylethyl), the above- described aryl group (particularly preferably a phenyl group), the above-described aralkyl group (particularly preferably a phenyl Cy lower alkyl group such as benzyl and phenethyl), and an arylalkenyl group (particularly preferably 2-phenylvinyl). Preferable examples of thes 1-substituted-Cs.j cycloalkyl group include 1-isopentylcyclobutyl, 1- 1sopropylcyclopentyl, 1-isobutylcyclopentyl, 1-isopentyl cyclopentyl, 1- cyclohexylmethylcyclopentyl, 1-methylcyclohexyl, 1-ethylcyclohexyl, 1-propylcyclohexyl, 1-1sopropylcyclohexyl, 1-butyleyclohexyl, 1-isobutyleyclohexyl, 1-pentylcyclohexyl, 1- isopentylcyclohexyl, 1-(2,2-dimethylpropyl)cyclohexyl, 1-(4-methylpentyl)cyclohexyl, 1- (2-ethylbutyl)cyclohexyl, 1-cyclopropylcyclohexyl, 1-bicyclohexyl, 1-phenylcyclohexyl, 1- cyclopropylmethylcyclohexyl, 1-cyclohexylmethylcyclohexyl, 1-(2- cyclopropylethyl)cyclohexyl, 1-(2-cyclopentylethyl)cyclohexyl, 1-(2- cyclohexylethyl)cyclohexyl, and 1-isopentylcycloheptyl. The straight chain or branched
Ci.10alkyl group is particularly preferable as a substituent at position 1.
The substituent for the “substituted or unsubstituted Cs.g cycloalkenyl group” for
Ris the same as that for the above “substituted or unsubstituted Cs_jg cycloalkyl group.”
Specifically, it means a cycloalkenyl group (especially cyclopentenyl and cyclohexenyl) that may have 1-4 substituents selected from the above-described straight chain or branched
Ci.0alkyl group (particularly preferably a Cys alkyl group such as methyl, ethyl, propyl, isopropyl, butyl. isobutyl, pentyl, isopentyl, 2,2-dimethylpropyl, 4-methylpentyl, or the like), the above-described straight chain or branched Cs.ip alkenyl group (particularly preferably a
Ca.galkenyl group such as 1-methylvinyl, 2-methylvinyl, 3-methyl-3-propenyl, and the like), the above-described Cs.jo cycloalkyl group (particularly preferably a Cs.7 cycloalkyl group
AMENDED SHEET: 13 JULY 2006 such as cyclopropyl, cyclopentyl, cyclohexyl, or the like), the above-described Cs.s cycloalkenyl group (particularly preferably a Cs. cycloalkenyl group like cyclopentenyl, cyclohexenyl, or the like), the above-described Cs.10 cycloalkyl Cy.joalkyl group (particularly preferably a Cs.7 cycloalkyl Ci.4 lower alkyl group such as cyclopropyl methyl, 2-cyclopropylethyl, 2-cyclopentylethyl, cyclohexylmethyl, 2-cyclohexylethyl, or the like), the above-described aryl group (particularly preferably a phenyl group), an oxo group, the above-described aralkyl group (particularly preferably a phenyl Ci. lower alkyl group such as benzyl, phenethyl, or the like), and arylalkenyl group (particularly preferably 2- phenylvinyl). Preferable examples of the cycloalkenyl group includes 1-isopropyl-2- cyclopentenyl, 1-isopropyl-3-cyclopentenyl, 1-isobutyl-2-cyclopentenyl, 1-isobutyl-3- cyclopentenyl, 1-isopentyl-2-cyclopentenyl, 1-isopentyl-3-cyclopentenyl, 1- cyclohexylmethyl-2-cyclopentenyl, 1-cyclohexylmethyl-3-cyclopentenyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, 1-methyl-2-cyclohexenyl, 1-methyl-3-cyclohexenyl, 1- ethyl-2-cyclohexenyl, 1-ethyl-3-cyclohexenyl, 1-propyl-2-cyclohexenyl, 1-propyl-3- cyclohexenyl, 1-isopropyl-2-cyclohexenyl, 1-isopropyl-3-cyclohexenyl, 1-butyl-2- cyclohexenyl, 1-butyl-3-cyclohexenyl, 1-isobutyl-2-cyclohexenyl, 1-isobutyl-3- cyclohexenyl, 1-pentyl-2-cyclohexenyl, 1-pentyl-3-cyclohexenyl, I-isopentyl-2- cyclohexenyl, 1-isopentyl-3-cyclohexenyl, 1-(2,2-dimethylpropyl)-2-cyclohexenyl, 1-(2,2- dimethylpropyl)-3-cyclohexenyl, 1-(4-methylpentyl)-2-cyclohexenyl, 1-(4-methylpentyl)-3- cyclohexenyl, 1-cyclopropyl-2-cyclohexenyl, 1-cyclopropyl-3-cyclohexenyl, 1-cyclohexyl- 2-cyclohexenyl, 1-cyclohexyl-3-cyclohexenyl, 1-phenyl-2-cyclohexenyl, 1-phenyl-3- cyclohexenyl, 1-cyclopropylmethyl-2-cyclohexenyl, 1-cyclo propylmethyl-3-cyclohexenyl, 1-cyclohexylmethyl-2-cyclohexenyl, 1-cyclohexylmethyl-3-cyclohexenyl, 1-(2- cyclopropylethyl)-2-cyclohexenyl, 1-(2-cyclopropylethyl)-3-cyclohexenyl, 1-(2- cyclopentylethyl)-2-cyclohexenyl, 1-(2-cyclopentylethyl)-3-cyclohexenyl, 1-(2- cyclohexylethyl)-2-cyclohexenyl, and 1-(2-cyclohexylethyl)-3-cyclohexenyl. There is no special restriction on the substitution position, but the particularly preferred position is position 1. Any one of the above substituents may be used, but the straight chain or branched Ci.y0 alkyl group or the Cs.10 cycloalkyl C;.4 alkyl group is particularly preferred.
A particularly preferable example of the substituted Cs.g cycloalkenyl group is a 1-substituted-Cs.g cycloalkenyl group. The “1-substituted-Cs.s cycloalkenyl group” means a cycloalkenyl groups (particularly preferably a Cs.¢ cycloalkenyl group such as cyclopentenyl or cyclohexenyl) that is substituted at position 1 with substituents selected from the above- described straight chain or branched Cy.jo alkyl group (particularly preferably a Cy. alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, 2,2- dimethyl propyl, and 4-methylpentyl), the above-described straight chain or branched Ca. alkenyl group (particularly preferably a Cas alkenyl group such as 1-methylvinyl, 2-
methylvinyl, or 3-methyl-3-propenyl), the above-described Cs.jo cycloalkyl group (particularly preferably a Cs.; cycloalkyl group such as cyclopropyl, cyclopentyl, or cyclohexyl), the above-described Cs.g cycloalkenyl group (particularly preferably a Css cycloalkenyl group such as cyclopentenyl or cyclohexenyl), the above-described Cs.10 cycloalkyl Cy.1p alkyl group (particularly preferably a Cs.7 cycloalkyl Cy.4 lower alkyl group such as cyclopropylmethyl, 2-cyclopropylethyl, 2-cyclopentylethyl, cyclohexylmethyl, or 2- cyclohexylethyl), the above-described aryl group (particularly preferably a phenyl group), the above-described aralkyl group (particularly preferably a phenyl C14 lower alkyl group such as benzyl or phenethyl), and the above-described arylalkenyl group (particularly preferably a 2-phenylvinyl group). Preferable examples of the 1-substituted-Cs.g cycloalkenyl group include 1-isopropyl-2-cyclopentenyl, 1-isopropyl-3-cyclopentenyl, 1- isobutyl-2-cyclopentenyl, 1-isobutyl-3-cyclopentenyl, 1-isopentyl-2-cyclopentenyl, 1- isopentyl-3-cyclopentenyl, 1-cyclohexylmethyl-2-cyclopentenyl, 1-cyclohexylmethyl-3- cyclopentenyl, 1-methyl-2-cyclohexenyl, 1-methyl-3-cyclohexenyl, 1-ethyl-2-cyclohexenyl, l-ethyl-3-cyclohexenyl, 1-propyl-2-cyclohexenyl, 1-propyl-3-cyclohexenyl, 1-isopropyl-2- cyclohexenyl, 1-isopropyl-3-cyclohexenyl, 1-butyl-2-cyclohexenyl, 1-butyl-3-cyclohexenyl, 1-isobutyl-2-cyclohexenyl, 1-isobutyl-3-cyclohexenyl, |-pentyl-2-cyclohexzenyl, 1-pentyl-3- cyclohexenyl, 1-isopentyl-2-cyclohexenyl, 1-isopentyl-3-cyclohexenyl, 1-(2,2- dimethylpropyl)-2-cyclohe:enyl, 1-(2,2-dimethylpropyl)-3-cyclohexenyl, 1-(4- methylpentyl)-2-cyclohexenyl, 1-(4-methylpentyl)-3-cyclohexenyl, 1-cyclopropyl-2- cyclohexenyl, 1-cyclopropyl-3-cyclohexenyl, 1-cyclohexyl-2-cyclohexenyl, 1-cyclohexyl- 3-cyclohexenyl, 1-phenyl-2-cyclohexenyl, 1-phenyl-3-cyclohexenyl, 1-cyclopropylmethyl- 2-cyclohexenyl, 1-cyclopropylmethyl-3-cyclohexenyl, 1-cyclohexylmethyl-2-cyclohexenyl, 1-cyclohexylmethyl-3-cyclohexenyl, 1-(2-cyclopropylethyl)-2-cyclohexenyl, 1-(2- cyclopropylethyl)-3-cyclohexenyl, 1-(2-cyclopentylethyl)-2-cyclohexenyl, 1-(2- cyclopentylethyl)-3-cyclohexenyl, 1-(2-cyclohexylethyl)-2-cyclohexenyl, and 1-(2- cyclohexylethyl)-3-cyclohexenyl. The straight chain or branched Ci.10 alkyl group is particularly preferable as a substituent at position 1.
The “substituted or unsubstituted Cs.1o cycloalkyl C,.jo alkyl group” for R means a Cs.jocycloalkyl Ci.jpalkyl group (particularly preferably cyclohexylmethyl, 1- cyclohexylethyl, 1-cyclohexyl-1-methylethyl, 1-cyclohexyl-2-methylpropyl, 1-cyclohexyl- 3-methylbutyl, 1-cyclohexylhexyl, 1-cyclohexyl-4-methylpentyl, and 1-cyclohexylheptyl),
C).10 alkyl group of which is straight chain or branched and which may have 1-4 substituents selected from the above-described Cs.io cycloalkyl group (particularly preferably a Cs. cycloalkyl group such as cyclopentyl or cyclohexyl), the above-described
Cs.g cycloalkenyl group (particularly preferably a Cs 7 cycloalkenyl group such as cyclopentenyl or cyclohexenyl), and the above-described aryl group (particularly preferably a phenyl group). There is no special restriction on the substitution position. The above- described substituents may be placed at the straight chain or branched C10 alkyl moiety.
Preferable examples of the Cs.10 cycloalkyl Cio alkyl group include cyclohexylmethyl, 1- cyclohexylethyl, cyclohexylcyclopentylmethyl, dicyclohexylmethyl, 1-cyclohexyl-1- methylethyl, 1-cyclohexyl-2-methylpropyl, 1-cyclohexyl-3-methylbutyl, 1-cyclohexyl-4- methylpentyl, 1-cyclohexylhexyl, and 1-cyclohexylheptyl.
The “substituted or unsubstituted aryl group” for R means an aryl group (particularly preferably a phenyl group) that may have 1-4 substituents selected from the above-described straight chain or branched Cy.¢alkyl group (particularly preferably a tert- butyl group), the above-described halogen atom (particularly preferably fluorine and chlorine), and a nitro group. Preferable examples of the aryl group are phenyl, 2- chlorophenyl, 4-nitrophenyl, and 3,5-di-tert-butylphenyl.
The “substituted or unsubstituted aralkyl” for R means an aralkyl group (particularly preferably benzyl, benzhydryl, and trityl) which may have substituents selected from the above-described halogen atom (particularly preferably fluorine and chlorine), a nitro group, and a hydroxy group, and in which the C,.4 lower alkyl group is straight chain or branched. There is no special restriction on the position of substitution. The straight chain or branched C4 lower alkyl moiety may be substituted. Preferable examples of the aralkyl group are benzyl and trityl.
The “substituted or unsubstituted 5- or 6-membered heterocyclic group having 1- 3 nitrogen, oxygen or sulfur atoms” for R means the above-described heterocyclic group that may have 1-4 substituents selected from the above-described straight chain or branched
Cc alkyl group (particularly preferably a tert-butyl group), the above-described halogen atom (particularly preferably fluorine and chlorine), and a nitro group. The heterocyclic group is preferably an aromatic heterocyclic group, particularly preferably furyl, thienyl, and pyridyl.
The “substituted or unsubstituted straight chain or branched C,.o alkyl group” for R, means a straight chain or branched C;.jo alkyl group that may have a substituent selected from the above-described halogen atom (particularly preferably fluorine and chlorine), the above-described C.4 lower alkoxy group (particularly preferably a methoxy group), an amino group that may be substituted with the above-described C;.4 lower alkyl group (particularly preferably a methyl group), the above-described acyl group (particularly preferably an acetyl group), or a hydroxyl group, the above-described Cy.4 lower alkylthio group (particularly preferably a methylthio group), a carbamoyl group, a hydroxyl group, an acyloxy group having the above-described acyl group (particularly preferably an acetyloxy group), a carboxyl group, an acyl group (particularly preferably a methoxycarbonyl group), and an aryloxy group having the above-described substituted or unsubstituted aryl group
(particularly preferably a phenoxy group and a 4-chlorophenoxy group). Preferable examples of the alkyl group include methyl, chloromethyl, ethyl, isopropyl, 1-methyl-2- pentyl, octyl, methoxymethyl, dimethylaminomethyl, acetylaminomethyl, 1-acetyl aminoethyl, 1-acetylamino-2-methylpropyl, 1-acetylamino-3-methylbutyl, 1-acetylamino-3- methylthiopropyl, 1-acetylamino-3-carbamoylpropyl, 1-hydroxy-1-methylethyl, 1- acetyloxy-1-methylethyl, 4-carboxybutyl, 2-methoxycarbonylethyl, phenoxymethyl, and 4- chlorophenoxymethyl.
The “C4 lower alkoxy group” for R, is preferably a methoxy group and a tert- butoxy group.
The “C 1.4 lower alkylthio group” for R, is preferably a methylthio group.
The “substituted or unsubstituted amino group” for R; means an amino group that may have a substituent selected from the above-described Cy.4 lower alkyl group (particularly preferably ethyl, isopropyl, and tert-butyl), the above-described acyl group (particularly preferably acetyl and benzoyl), and the above-described aryl group (particularly preferably phenyl and 4-methoxyphenyl) that may be substituted with the above-described Ci.4 lower alkoxy group. Preferable examples of the amino group are ethylamino, isopropylamino, tert-butylamino, phenylamino, and 4-methoxyphenylamino.
The “substituted or unsubstituted ureido group” for Ry means a urcido group that may have a substituent selected from the above-described C,.4 lower alkyl group (particularly preferably methyl and ethyl), the above-described acyl group (particularly preferably acetyl and benzoyl), and the above-described aryl group (particularly preferably phenyl and 4-methoxyphenyl) that may be substituted with the above-described C).4 lower alkoxy group, with an N,N’-diphenylureido group being preferred.
The “substituted or unsubstituted Cs.;o cycloalkyl group” for R) means a Cs.jo cycloalkyl group (particularly preferably cyclopropyl and cyclohexyl) that may have a substituent selected from the above-described straight chain or branched C;.1o alkyl group (particularly preferably methyl, tert-butyl, and isopentyl), an amino group, an amino group (particularly preferably methylamino, ethylamino, acetylamino, and benzylamino) that may be substituted with the above-described C.4 lower alkyl or acyl groups. Preferable examples the cycloalkyl group are cyclopropyl, cyclohexyl, 1-methylcyclohexyl, 1- isopentylcyclohexyl, 1-aminocyclohexyl, 1-acetylaminocyclohexyl, and 4-tert- butylcyclohexyl.
The “substituted or unsubstituted Cs.1o cycloalkyl Ci.io alkyl group” for R, means a Ca. cycloalkyl C.1 alkyl group which may have a substituent selected from the above-described Cs.o cycloalkyl group (particularly preferably cyclopentyl and cyclohexyl), the above-described Cs. cycloalkenyl group (particularly preferably cyclopentenyl and cyclohexenyl), and the above-described aryl group (particularly preferably a phenyl group)
and in which the Cy; alkyl moiety is straight chain or branched. There is no special restriction on the position of substitution. The straight chain or branched Cy.j0 alkyl moiety may be substituted. A cyclohexylmethyl group is preferred as the Cs.y, cycloalkyl Ci.1o alkyl group.
The “substituted or unsubstituted aryl group” for Ry means an aryl group (particularly preferably phenyl and naphthyl) that may have a substituent selected from the above-described straight chain or branched C,.¢ alkyl group (particularly preferably methyl and tert-butyl group), the above-described halogen atom (particularly preferably fluorine and chlorine), a nitro group, a hydroxyl group, the above-described Cy. lower alkoxy group (particularly preferably a methoxy group), and the above-described acyl group (particularly preferably a 2-(1-isopentylcyclohexanecarbonylamino)phenylthiocarbonyl group).
Preferable examples of the aryl group include phenyl, 1-naphthyl, 2-naphthyl, 2- chlorophenyl, 2,6-dichlorophenyl, 2,6-dimethylphenyl, 2-methoxyphenyl, 2-nitrophenyl, 4- nitrophenyl, 3,5-di-tert-butyl-4-hydroxyphenyl, and 4-[2-(1- isopentylcyclohexanecarbonylamino)phenylthiocarbonyl] phenyl.
The “substituted or unsubstituted aralkyl group™ for R) means an aralkyl group (particularly preferably benzyl, phenethyl, 3-phenylpropyl, naphthylmethyl, and biphenylmethyl) that may have a substituent selected from the above-described halogen atom (particularly preferably fluorine and chlorine), a nitro group, an amino group (particularly preferably amino, acetylamino, pivaloylamino, 1-methylcyclohexanecarbonyl- amino, tert-butoxycarbonylamino, and benzoylamino) that may be substituted with the above-described C4 lower alkyl group or the above-described acyl group, and a hydroxyl group, and in which the C4 lower alkyl group are straight chain or branched. There is no : special restriction on the position of substitution. The straight chain or branched C4 lower alkyl moiety may be substituted. Preferable examples of the aralkyl group include benzyl, phenethyl, 3-phenylpropyl, 2-naphthylmethyl, 4-biphenylmethyl, benzhydryl, 2- chlorophenylmethyl, 3-chlorophenylmethyl, 4-chlorophenylmethyl, 2-nitrophenylmethyl, 4- nitrophenyimethyl, 2-pivaloylaminophenylmethyl, 2-(1- methylcyclohexanecarbonylamino)phenylmethyl, 2-tert-butoxy- carbonylaminophenylmethyl, 3-acetylaminophenylmethyl, 3-(1- methylcyclohexanecarbonylamino)phenylmethyl, a-aminobenzyl, a-acetylaminobenzyl, a- (1-methylcyclohexanecarbonylamino)benzyl, a-benzoylaminobenzyl, a-aminophenethyl, o- acetylaminophenethyl, and 1-acetylamino-2-(4-hydroxyphenyl) ethyl.
The “substituted or unsubstituted arylalkenyl group” for R) means an arylalkenyl group (particularly phenylvinyl) that may have a substituent selected from the above- described straight chain or branched Cy. lower alkyl group (particularly preferably methyl
AMENDED SHEET: 13 JULY 2006 and tert-butyl), the above-described halogen atom (particularly preferably fluorine and chlorine), a nitro group, and a hydroxyl group, with a 2-phenylvinyl group being preferred.
The “substituted or unsubstituted arylthio group” for Ri means an arylthio group (particularly preferably a phenylthio group) that may have a substituent selected from the above-described halogen atom (particularly preferably fluorine and chlorine), a nitro group, and an amino group that may be substituted with the above-described C)4 lower alkyl group or the above-described acyl group (particularly preferably amino, acetylamino, pivaloylamino, 1-methylcyclohexanecarbonylamino, and benzoylamino), a hydroxyl group, and the above-described halo-C).4 lower alkyl group (particularly preferably a trifluoromethyl group). Preferably examples of the arylthio group include phenylthio, 2- pivaloylaminophenylthio, 2-(1-methylcyclohexanecarbonylamino)phenylthio, and 2-(1- methyl cyclohexanecarbonylamino-4-trifluoromethyl)phenylthio.
The “substituted or unsubstituted 5- or 6-membered heterocyclic ring groups with 1-3 nitrogen, oxygen, or sulfur atoms” for R; means heterocyclic ring groups (particularly preferably an aromatic heterocyclic group such as pyridyl or a non-aromatic heterocyclic group such as piperidyl or pyrrolidinyl) that may have substituents selected from the above-described straight chain or branched Cig alkyl group (particularly preferably a methyl group), a halogen atom (particularly preferably fluorine and chlorine), the above-described acyl group (particularly preferably acetyl and benzoyl), and an oxo group. Preferable examples thereof are 3-pyridyl, 1-methyl-4-piperidyl, 1-acetyl-4- piperidyl, 5-ox0-2-pyrrolidinyl, 1-acetyl-2-pyrrolidinyl, and 1-benzoyl-2-pyrrolidinyl. A 4- piperidyl group such as 1-methyl-4-piperidyl or 1-acetyl-4-piperidyl group is particularly preferred.
The “substituted or unsubstituted 5- or 6-membered heteroarylalkyl group” for
Rj means the above-described heteroarylalkyl group (particularly preferably a 2-thienyl group) that may be substituted with the above-described straight chain or branched Cj.¢ alkyl group (particularly preferably a methyl group) and the above-described halogen atom (particularly preferably fluorine and chlorine). A 2-thienyl group is preferred.
The “substituted or unsubstituted C4 lower alkyl group” for Ry means a C4 lower alkyl group (particularly preferably a methyl group) that may have 1-3 substituents selected from the above-described C4 lower alkoxy group (particularly preferably a methoxy group), an amino group that may be substituted with the above-described C4 lower alley! or acyl group (particularly preferably a dimethylamino group), the above- described C.4 lower alkylthio group (particularly preferably a methylthio group), a carbamoyl group, a hydroxyl group, a carboxyl group, the above-described acyl group (particularly preferably a methoxycarbonyl group), and the above-described heterocyclic group (particularly preferably an aromatic heterocyclic group such as thieny! or a non-
AMENDED SHEET: 13 JULY 2006 aromatic heterocyclic group such as tetrahydrofuryl). A tetrahydrofurylmethyl group is preferred.
The “substituted or unsubstituted aryl group” for Ra is the same as that for Ri.
Preferable examples thereof are a phenyl group, a halogenated phenyl group, an acylamino-
S substituted phenyl group, and the like.
The “halogen atom” for Xj, Xz, Xa, and X4 means a halogen atom including fluorine, chlorine, bromine, and the like, with fluorine and chlorine being preferred.
The “Cj.s lower alkyl group” for Xi, Xa, Xs, and Xs is preferably a methyl group.
The “halo-C,.4 lower alkyl group” for Xi, Xa, Xs, and X, means a C,.4 lower alkyl group (particularly preferably a methyl group) substituted with the above-described halogen atom (particularly preferably fluorine and chlorine). A trifluoromethyl group is preferred.
The “Cj.¢ lower alkoxy group” for X,, Xa, X3, and X4 is preferably a methoxy group.
The “acyl group” for Xi, Xo, Xs, and Xy is preferably a benzoyl group.
The “aryl group” for Xi, Xz, Xs, and Xa is preferably a phenyl group.
Preferably, the CETP inhibitor is a compound selected from the group consisting of N-(2-mercaptophenyl)-1-isopentylcyclohexanecarboxamide; N~(2-mercaptophenyl)-1- methylcyclohexanecarboxamide; N-(2-mercaptophenyl)-1- isopentylcyclopentanecarboxamide; N-(2-mercaptophenyl)-1- isopropylcyclohexanecarboxamide; N-(4,5-dichloro-2-mercaptophenyl)-1- isopentyleyclohezanecarboxamide; N-(4,5-dichloro-2-mercaptophenyl)-1- isopentylcyclopentanecarboxamide; N-(2-mercapto-5-methylphenyl)-1- isopentylcyclohexanecarboxamide; N-(2-mercapto-4-methylphenyl)-1- isopentylcyclohexanecarboxamide; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl] thioacetate; S-[2-(1-methylcyclohexanecarbonylamino)phenyl] 2,2-dimethylthiopropionate;
S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl] 2,2-dimethylthiopropionate; S-[2-(1- isopentylcyclohexanecarbonylamino)phenyl] 2-acetylamino-3-phenylthiopropionate; S-[2- (1-isopentylcyclohexanecarbonylamino)phenyl] 3-pyridinethiocarboxylate; S-{2-(1- isopentylcyclohexanecarbonylamino)phenyl] chlorothioacetate; S-[2-(1- isopentylcyclohexanecarbonylamino)phenyl] methoxythioacetate; S-[2-(1- isopentylcyclohexanecarbonylamino)phenyl] thiopropionate; S-[2-(1- isopentylcyclohexanecarbonylamino)phenyl] phenoxythioacetate; S-[2-(1- isopentylcyclohexanccarbonylamino)phenyl] 2-methylthiopropionate; S-[2-(1- isopentylcyclohexanecarbonylamino)phenyl] 4-chlorophenoxythioacetate; S-[2-(1- isopentylcyclohexanecarbonylamino)phenyl] cyclopropanethiocarboxylate; S-[2-(1- isopentylcyclohexanecarbonylamino)phenyl] 2-acetylamino-4-carbamoylthiobutyrate; S-[2-
(I-isopentylcyclohexanecarbonylamino)phenyl] 2-hydroxy-2-methylthiopropionate; S-[2- (1-isopentylcyclopentanecarbonylamino)phenyl] 2,2-dimethylpropionate; S-[2-(1- isopentylcyclopentanecarbonylamino)phenyl] thioacetate; S-[4,5-dichloro-2-(1- isopentylcyclohexanecarbonylamino)phenyl] 2,2-dimethylthiopropionate; S-[4,5-dichloro- 2-(l-isopentylcyclopentanecarbonylamino)phenyl] 2,2-dimethylthiopropionate; S-[2-(1- isopentylcyclohexanecarbonylamino)-4-trifluoromethylphenyl] 2,2-dimethylthiopropionate;
O-methyl S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl] monothiocarbonate; S-[2- (1-methylcyclohexanecarbonylamino)phenyl] S-phenyl dithiocarbonate; S-[2-(1- 1sopentylcyclohexanecarbonylamino)phenyl] N-phenylthiocarbamate; S-[4,5-dichloro-2-(1- cyclopropylcyclohexanecarbonylamino)phenyl] 2,2-dimethylthiopropionate; S-[4,5- dichloro-2-(1-pentylcyclohexanecarbonylamino)phenyl] 2,2-dimethylthiopropionate; S- [4,5-dichloro-2-(1-cyclopropylmethylcyclohexanecarbonylamino)phenyl] 2,2- dimethylthiopropionate; S-[4,5-dichloro-2-(1- cyclohexylmethylcyclohexanecarbonylamino)phenyl] 2,2-dimethylthiopropionate; S-[4,5- dichloro-2-(1-isopropylcyclohexanecarbonylamino)phenyl] 2,2-dimethylthiopropionate; S- [4,5-dichloro-2-(1-isopentylcycloheptanecarbonylamino)phenyl] 2.2- dimethylthiopropionate; S-[4,5-dichloro-2-(1-isopentylcyclobutanecarbonylamino)phenyl] 2.2-dimethylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonyl amino)-4-nitrophenyl] 2.2-dimethylthiopropionate; S-[4-cyano-2-(1-isopentylcycloheranecarbonylamino)phenyl] 2,2-dimethylthiopropionate; S-[4-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl] 2,2-dimethylthiopropionate; S-[5-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl] 2.2-dimethylthiopropionate; S-[4-fluoro-2-(1-isopentylcyclohzx:anecarbonylamino)phenyl] 2 2-dimethylthiopropionate; S-[4,5-difluoro~2-(1- isopentylcyclohexanecarbonylamino)phenyl] 2,2-dimethylthiopropionate; S-{5-fluoro-2-(1- isopentylcyclohexanecarbonylamino)phenyl] 2,2-dimethylthiopropionate; N-(2- mercaptophenyl)-1-ethylcyclohexanecarboxamide; N-(2-mercaptophenyl)-1- propylcyclohexanecarboxamide; N-(2-mercaptophenyl)-1-butylcyclohexanecarboxamide;
N-(2-mercaptophenyl)-1-isobutylcyclohexanecarboxamide; S-[2-(1- isopentylcyclohexanecarbonylamino)phenyl] cyclohexanethiocarboxylate; S-[2-(1- isopentylcyclohexanecarbonylamino)phenyl] thiobenzoate; S-[2-(1- isopentylcyclohexanecarbonylamino)phenyl] S-carboxythiopentanoate; S-[2-(1- 1sopentylcyclohexanecarbonylamino)-4-methylphenyl] thioacetate; N-(2-mercaptophenyl)- 1-(2-ethylbutyl)cyclohexanecarboxamide; S-[2-([[1-(2- ethylbutyl)cyclohexyl]carbonylJamino)phenyl] 2-methylpropanethioate; S-[2-(1- isobutylcyclohexanecarbonylamino)phenyl] 2-methylthiopropionate; S-[2-[1-(2- ethylbutyl)cyclohexanecarbonylamino]phenyl] 1-acetylpiperidine-4-thiocarboxylate; S-[2- [1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl] thioacetate; S-[2-[1-(2-
AMENDED SHEET: 13 JULY 2006 ethylbutyl)cyclohexanecarbonylaminolphenyl} 2,2-dimethylthiopropionate; S-[2-[1-(2- ethylbutyl)cyclohexanecarbonylamino]phenyl] methoxythioacetate; S-[2-[1-(2- ethylbutyl)cyclohexanecarbonylamino]phenyl] 2-hydroxy-2-methylpropionate; S-[2-{1-(2- ethylbutyl)cyclohexanecarbonylamino]phenyl] 4-chlorophenoxythioacetate; S-[2-(1- isobutylcyclohexanecarbonylamino)phenyl] 4-chlorophenoxythioacetate; and S-[2-(1- isobutylcyclohexanecarbonylamino)phenyl] 1-acetylpiperidine-4-thiocarboxylate, or a prodrug compound, a pharmaceutically acceptable salt, a hydrate, or a solvate thereof.
Most preferably, the CETP inhibitor is S-[2-([[1-(2- ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate (which also is known as propanethioic acid, 2-methyl-, S-[2-[{[1-(2- ethylbutyl)cyclohexyl]carbonyl]Jamino]phenyl]ester; S-[2-[1-(2- ethylbutyl)cyclohexanecarbonylamino]phenyl] 2-methylthiopropionate, or JTT-705) (herein referred to as Compound I). Compound I has the following structural formula:
Compound I
HC
HC
CHa HN 0
NS
HaC 0]
S-[2-(I[1-(2-ethylbutyl)cyclohexyl}carbonylJamino)phenyl] 2- methylpropanethioate has been shown to be an inhibitor of CETP activity in humans (de
Grooth et al., Circulation, 105, 2159-2165 (2002)) and rabbits (Shinkai et al., J. Med. Chem., 43, 3566-3572 (2000); Kobayashi et al., Atherosclerosis, 162, 131-135 (2002); and
Okamoto et al., Nature, 406(13), 203-207 (2000)). S-[2-([[1-(2- ethylbutyl)cyclohexyl]carbonyljamino)phenyl] 2-methylpropanethioate has been shown to increase plasma HDL cholesterol in humans (de Grooth et al., supra) and in rabbits (Shinkai et al., supra, Kobayashi et al., supra; Okamoto et al., supra). Moreover, S-[2-([[1-(2- ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate has been shown to decrease LDL cholesterol in humans (de Grooth et al., supra) and rabbits (Okamoto et al., supra). Additionally, S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2- methylpropanethioate inhibits the progression of atherosclerosis in rabbits (Okamoto et al, supra). S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyljamino)phenyl] 2-methylpropanethioate,
as well as methods of making and using the compound, are described in U.S. Patent 6,426,365.
While not wishing to be bound by any particular theory, it is hypothesized that within the body of a patient, Compound I is hydrolyzed in plasma, the liver, and/or the small intestine to form S-[2([[1-(2-ethylbutyl)cyclohexyl] carbonyl]amino)phenyl] thiol (herein referred to as Compound II). It is known that low molecular weight thiol components (i.e., R-SH), such as cysteine and glutathione, and high molecular weight thiol components (i.., Prot-SH), such as peptides and proteins (€.g., enzymes and cell membranes), exist in the body as mixed disulfides containing an oxidized disulfide bond (S-S bond) between or within the molecule (see, €.g., Shimade et al., J Chromatogr. B, 659, 227 (1994)). Therefore, it is hypothesized that within the body of a patient, Compound II is conjugated with low or high molecular weight thiols to yield mixed disulfides or to yield dimers of Compound II. Since these forms are in an oxidation-reduction equilibrium with each other via Compound II, all of these forms, as well as Compound II, are collectively, but not exclusively, considered and referred to hereafter as the active form of Compound I.
The following scheme depicts the above-described hypothesis.
®] = 2 5 i 5 5 g of 3 wD a = 8 = g 3 — 3 ESB
SE 23S
Zz Egg Q 72] tS L0.=
T 5 = ht o o = S 222 Td | OE= ° 2 51 ed B= T ® £5 < SE 8 2 * | Zz oo
Q, » 2 =
I | 8 x < = 3
I» 2 © b= g oO = NY - Esk - + = E28 p= = sm = U2, XI 2 2 & —_— oO 2 = 5 x g 9 0 x (@} 3 Q, I
Q = T 3
T z g 0 [32d
T=
O z EB bt
Fr 2 8 go
J 2 §< x | oO oO [ot] ~_
While the administration of Compound I is a particularly preferred embodiment of the invention, the invention also contemplates the administration of other compounds that will yield the active form of Compound J, i.e., other prodrugs of the active form of
Compound I. Such prodrugs, for example, can be compounds that have different mercapto- protecting groups, but that still result in the formation of the active form of Compound I (e.g., Compound II) in the body of a patient (i.e., in vivo). The term “mercapto-protecting groups” refers to commonly used mercapto-protecting groups (e.g., as described in Wolman,
The Chemistry of the Thiol Group, D. Patai, Ed., Wiley-Interscience, New York, 1974).
Any organic residues that can be dissociated in vivo may be used without particular restriction. Examples of particularly suitable mercapto-protecting groups are described in
U.S. Patent 6,426,365. The invention further contemplates the administration of Compound
I’ (wherein R’ signifies an organic residue other than an isopropyl group) so as to yield the active form of Compound 1.
H.C
HaC
HN 0]
R s ? he 0}
Compound I'
In addition, Compounds III, IV, and V (wherein R signifies an organic residue and Prot signifies a peptide or protein), which are believed to be in equilibrium with
Compound II in vivo, similarly can be directly administered to the patient.
The CETP inhibitor (e.g., Compound I) can be in any suitable form (e.g., as a solid or a liquid, in crystalline or amorphous form, or any combination thereof). In a preferred embodiment, the CETP inhibitor is a solid in crystalline or amorphous form. The term “amorphous” signifies a non-crystalline state. The term “combination thereof” as applied to the amorphous or crystalline states of the CETP inhibitor refers to a mixture of amorphous and crystalline forms of the CETP inhibitor. A major portion of the CETP inhibitor can be in amorphous or crystalline form. As used herein, the term “a major portion” of the CETP inhibitor means more than 50% of the CETP inhibitor in the composition. For example, a major portion of the CETP inhibitor in the composition can be in crystalline form. Alternatively, the CETP inhibitor in the composition can be
“substantially amorphous” (i.e., the amount of the CETP inhibitor in crystalline form does not exceed about 10%) or “substantially crystalline” (i.., the amount of the CETP inhibitor in amorphous form does not exceed about 10%). Preferably, the CETP inhibitor is at least about 50% (e.g., at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or actually about 100%) crystalline. The amount of crystalline CETP inhibitor can be measured by powder X-ray diffraction, Scanning Electron Microscope (SEM) analysis, differential scanning calorimetry (IDSC), or any other standard quantitative measurement.
A substantial number of CETP inhibitors have a low aqueous solubility, a low bioavailability, and/or a slow rate of absorption such that it is desirable to increase their concentration in an aqueous environment of use. As used herein, the term “bioavailability” generally means the rate and extent to which the active ingredient, or active form thereof, is absorbed from a drug product and becomes available at the site of action. See U.S. Code of
Federal Regulations, Title 21, Part 320.1 (2001 ed.). For oral dosage forms, bioavailability relates to the processes by which the active ingredient is released from the oral dosage form, e.g., a tablet, converted to the active form (if the active ingredient is not already the active form), and moved to the site of action, e.g., absorbed into the systemic circulation.
Oral delivery of many CETP inhibitors is often ditficult because the aqueous solubility of CETP inhibitors is extremely low (i.e., the CETP inhibitor is substantially water-insoluble). The terms “extremely low aqueous solubility” and “substantially water- insoluble” signify that the CETP inhibitor has a maximum aqueous solubility of less than about 10 pg/mL (e.g., less than about 5 pg/mL, less than about 2 pg/mL, less than about 1 pg/mL, less than about 0.5 pg/mL, less than about 0.1 pg/mL, less than about 50 ng/mL, less than about 20 ng/mL, or less than about 10 ng/mL) at any physiologically relevant pH (e.g., pH 1-8) and at about 22°C. For example, the solubility of Compound I in water is less than about 0.0001 mg/mL. Such low solubilities are a direct consequence of the particular structural characteristics of the species that bind to CETP, and thus act as CETP inhibitors.
This low solubility is primarily due to the hydrophobic nature of CETP inhibitors.
Thus, the hydrophobic and insoluble nature of CETP inhibitors poses a particular challenge for oral delivery. Achieving therapeutic drug levels in the blood by oral dosing of practical quantities of drug generally requires a large enhancement in drug concentrations in the gastrointestinal fluid and a resulting large enhancement in bioavailability. Additionally, the CETP inhibitors can have a very high dose-to-solubility ratio. Extremely low solubility often leads to poor or slow absorption of the drug from the fluid of the gastrointestinal tract, when the drug is dosed orally in a conventional manner. For extremely low solubility drugs,
poor absorption generally becomes progressively more difficult as the dose (mass of drug given orally) increases.
The CETP inhibitors are characterized by a low melting point. The CETP inhibitors preferably have a melting point of about 150° C or less (e.g., about 140° C or less, about 130° C or less, about 120° C or less, about 110° C or less, about 100° C or less, about 90° C or less, about 80° C or less, or about 70° C or less. For example, Compound I has a melting point of about 63-65° C.
As a consequence of one or more of these properties, CETP inhibitors typically have very low absolute bioavailabilities. Specifically, the absolute bioavailibility of CETP inhibitors when dosed orally in their undispersed state is less than about 10% (e.g., less than about 9%, less than about 8%, less than about 7%, or less than about 6%) and more often less than about 5% (¢.g., less than about 4%, less than about 3%, less than about 2%, or less than about 1%).
To overcome the very low absolute bioavailabilities associated with CETP inhibitors, the invention provides a pharmaceutical composition comprising a CETP inhibitor and one or more water-insoluble concentration-enhancing additives.
Advantageously, it has been found that inclusion of the water-insoluble concentration- enhancing additive dramatically improves the bioavailability of the CETP inhibitor.
The water-insoluble concentration-enhancing additive can be any suitable additive that enhances the bioavailability of the CETP inhibitor relative to the administration of the CETP inhibitor in the absence of the additive. The concentration- enhancing additive preferably is a polymer. By “water-insoluble” additive it is meant that the additive has a maximum aqueous solubility of less than about 10 pg/mL at any physiologically relevant pH (e.g., pH 1-8) and at about 22°C. By “concentration-enhancing additive(s)” it is meant that the additive (e.g., polymer) enhances the bioavailability of the
CETP inhibitor relative to the administration of the CETP inhibitor in the absence of the concentration-enhancing additive(s). For example, the presence of an additive in the pharmaceutical composition preferably enhances the concentration of the CETP inhibitor (or active form thereof) in the aqueous environment of use (e.g., plasma, especially of a human) when compared to the administration of the CETP inhibitor in the absence of the additive. Thus, the additive can be considered a “concentration-enhancing additive” or, when such an additive is a polymer, a “concentration-enhancing polymer.”
The pharmaceutical composition comprising a CETP inhibitor and a water- insoluble concentration-enhancing additive is capable of achieving specific maximum concentrations and areas under the concentration-time curve (AUC) from time zero up to the last quantifiable concentration (0-t,) and/or from time zero to infinity (0-0) of the active form of the CETP inhibitor (e.g., the active form of Compound I) in the environment of use
(typically plasma, especially of a human), as discussed further in the description of the methods of use of the pharmaceutical compositions.
The amount of water-insoluble concentration-enhancing additive relative to the amount of CETP inhibitor present in the pharmaceutical composition depends on the CETP
S inhibitor and concentration-enhancing additive. The weight ratio of CETP inhibitor to additive can be from about 1:100 to about 10:1 (e.g., about 1:50, about 1:25, about 1:10, about 1:5, about 1:4; about 1:3, about 1:2, about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or ranges thereof). Preferably, the CETP inhibitor to additive weight ratio is about 2:1 to about 9:1, more preferably about 2:1 to about4:1. The CETP inhibitor to additive ratio that yields optimum results varies from
CETP inhibitor to CETP inhibitor and is best determined in in vitro dissolution tests and/or in vivo bioavailability tests.
An especially preferred water-insoluble concentration-enhancing additive is crospovidone (i.e., a synthetic homopolymer of cross-linked N-vinyl-2-pyrrolidone). Crospovidone can be present in the pharmaceutical composition in any suitable amount, desirably within the range of about 30% to about 100% (e.g., about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or ranges thereof) by weight of the CETP inhibitor (e.g., Compound I). In a preferred embodiment of the present invention, the weight ratio of
CETP inhibitor to crospovidone can be from about 1:1 to about 3.3:1, more preferably about 2:1to about 3:1. The amount of crospovidone in the pharmaceutical composition is important for disintegration and dissolution of the dosage form (e.g., tablet). For example, when the pharmaceutical composition comprises less than about 30% (e.g., less than about 25%, less than about 20%, less than about 15%, less than about 10%, or less than about 5%) of the CETP inhibitor by weight, the disintegration time of the tablet is delayed, and the resulting dissolved amount of the CETP inhibitor is decreased. The disintegration time and resulting dissolution amount are closely related to the absorbable amount of the CETP inhibitor in the gastrointestinal tract, which affects the efficacy level of the pharmaceutical composition.
The pharmaceutical composition comprising a CETP inhibitor and a water- insoluble concentration-enhancing additive (e.g., crospovidone) also can comprise one or more pharmacologically acceptable additives, such as pharmaceutically acceptable carriers or excipients and optionally other therapeutic agents (e.g., hydroxy-methylglutaryl coenzyme A reductase inhibitors) and/or components. For example, the CETP inhibitior can be used together with known pharmacologically acceptable carriers, excipients, diluents, extenders, disintegrants, stabililizers, preservatives, buffers, emulsifiers, aromatics, colorants, sweeteners, viscosity increasing agents, flavor improving agents, solubilizers, and other additives. These additives must be acceptable in the sense of being compatible with the other ingredients and not deleterious to the recipient thereof. Examples of additives for oral administration include cornstarch, lactose, magnesium stearate, talc, microcrystalline cellulose, stearic acid, povidone, dibasic calcium phosphate, sodium starch glycolate, hydroxypropyl cellulose (e.g., low substituted hydroxypropyl cellulose), hydroxypropylmethyl cellulose (e.g., hydroxypropylmethy! cellulose 2910), and sodium lauryl sulfate.
The pharmaceutical composition desirably is in the form of a mixture, preferably a solid mixture, which is prepared by mechanically mixing the CETP inhibitor and water-insoluble concentration-enhancing additive, as well as additional pharmacologically acceptable additives. The composition is preferably substantially homogeneous so that the CETP inhibitor is dispersed as homogeneously as possible throughout the composition. As used herein, “substantially homogeneous” means that the fraction of CETP inhibitor that is present in relatively pure domains within the composition is relatively small, for example, less than about 20%, less than about 15%, less that about 10%, or less than about 5% of the total amount of CETP inhibitor.
The preferred solid composition may have one or multiple glass transition temperatures (Tg). In one embodiment, the solid composition has a single glass transition temperature, which demonstrates that the composition is substantially homogeneous. Tg as used herein is the characteristic temperature where a glassy material, upon gradual heating, undergoes a relatively rapid (e.g., about 10 to about 100 seconds) physical change from a glass state to a rubber state. The T, of a material can be measured by several techniques, including by a dynamic mechanical analyzer (DMA), a dilatometer, dielectric analyzer, and by a differential scanning calorimeter (DSC). The exact values measured by each technique can vary somewhat but usually fall within 10°C to 30°C of each other. Regardless of the technique used, when a composition exhibits a single Tj, this indicates that the composition is substantially homogenous.
The pharmaceutical composition can be prepared by any suitable method, such as those methods well known in the art of pharmacy, for example, methods such as those described in Gennaro et al., Remington’s Pharmaceutical Sciences (18th ed., Mack
Publishing Co., 1990), especially Part 8: Pharmaceutical Preparations and their Manufacture.
Such methods include the step of bringing into association the CETP inhibitor with the other components of the pharmaceutical composition.
The pharmaceutical composition comprising the CETP inhibitor and water- insoluble concentration-enhancing additive can be made according to any suitable process.
Preferably, the manufacturing process includes mechanical processes such as milling and extrusion. Alternatively, the pharmaceutical composition can be prepared by melt processes,
such as high temperature fusion, solvent modified fusion, and melt-congeal processes; or solvent processes, such as non-solvent precipitation, spray coating, and spray-drying.
The pharmaceutical composition can provide controlled, slow release, or sustained release of the CETP inhibitor over a predetermined period of time. The controlled, slow release, or sustained release of the therapeutic compound can provide for a concentration of the CETP inhibitor, or the active form thereof, to be maintained in the bloodstream of the patient for a longer period of time. Such a pharmaceutical composition includes coated tablets, pellets, and capsules. Alternatively, the pharmaceutical composition can be in the form of a dispersion of the therapeutic compound in a medium that is insoluble in physiologic fluids or where the release of the therapeutic compound follows degradation of the pharmaceutical composition due to mechanical, chemical, or enzymatic activity.
The pharmaceutical composition can be, for example, in the form of a pill, capsule, or tablet, each containing a predetermined amount of the CETP inhibitor and preferably coated for ease of swallowing, in the form of a powder or granules. Preferably, the pharmaceutical composition is in the form of a tablet comprising the CETP inhibitor and the components of the tablet utilized and described in the Examples herein. For oral administration, fine powders or granules may contain diluting, dispersing, and or surface active agents and may be present, for example, in capsules or sachets in the dry state, or in tablets wherein binders and lubricants may be included. Components such as sweeteners, flavoring agents, preservatives (e.g., antimicrobial preservatives), suspending agents, thickening agents, and/or emulsifying agents also may be present in the pharmaceutical composition. A component of the formulation may serve more than one function.
Oral delivery methods are often limited by chemical and physical barriers imposed by the body, such as the varying pH in the gastrointestinal tract, exposure to enzymes, and the impermeability of the gastrointestinal membranes. The oral administration of the pharmaceutical composition may also include the co-administration of adjuvants. For example, nonionic surfactants such as polyoxyethylene oleyl ether and n- hexadecyl! polyethylene ether can be administered with or incorporated into the pharmaceutical composition to artificially increase the permeability of the intestinal walls.
Enzymatic inhibitors also can be administered with or incorporated into the pharmaceutical composition. :
The pharmaceutical composition can be administered in any suitable manner.
Preferably, the composition is administered with food. The term “with food” is defined to mean, in general, the condition of having consumed food during the period between from about 1 hour prior to the administration of the pharmaceutical composition comprising the
CETP inhibitor to about 2 hours after the administration of the composition. Preferably, the food is a solid food with sufficient bulk and fat content that it is not rapidly dissolved and absorbed in the stomach. More preferably, the food is a meal, such as breakfast, lunch, or dinner.
Advantageously, the pharmaceutical composition is administered any time of day with food. The food can be consumed at any time during the period between from about 1 hour prior to the administration of the composition to about 2 hours after the administration of the composition. For example, the food can be consumed within the time period of about 1 hour, about 45 minutes, about 30 minutes, about 15 minutes, about 10 minutes, or about 5 minutes prior to the administration of the composition. Similarly, the food can be consumed within the time period of about 5 minutes, about 10 minutes, about minutes, about 30 minutes, about 45 minutes, about 1 hour, about 1.25 hours, about 1.5 hours, about 1.75 hours, or about 2 hours after the administration of the composition. More preferably, the administration of the composition to the patient is immediately after the consumption of food (e.g. within about 1 minute after food consumption) up to about 1 hour 15 after food consumption. Ideally, the pharmaceutical composition comprising the CETP inhibitor is administered at substantially the same time as the consumption of the food. The administration of the pharmaceutical composition with food can increase the bioabailability of the CETP inhibitor in the aqueous environment of use.
The terms “without food” or “fasted” are defined to mean the condition of not having consumed food within the time period of about 1 hour prior to the administration of the composition to about 2 hours after the administration of the composition.
The pharmaceutical composition can be used to treat or prevent a cardiovascular disorder, including, but not limited to, atherosclerosis, peripheral vascular disease, dyslipidemia (c.g., hyperlipidimia), hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, cardiovascular disease, coronary heart disease, coronary artery disease, hyperlipidoproteinemia, vascular complications of diabetes, obesity or endotoxemia in a mammal, especially a human (i.e., a male or female human).
Accordingly, the invention provides a method for the treatment or prophylaxis of a cardiovascular disorder in a mammal, which method comprises administering to a mammal (preferably a mammat in need thereof) a therapeutically effective amount of the pharmaceutical composition. The mammal preferably is a human (i.e., a male or female human). The human can be of any race (e.g., Caucasian or Oriental). The cardiovascular disorder preferably is selected from the group consisting of atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, angina,
ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, and vascular complications of diabetes, obesity or endotoxemia in a mammal. More preferably, the cardiovascular disorder is selected from the group consisting of cardiovascular disease, coronary heart disease, coronary artery disease, hypoalphalipoproteinemia, hyperbetalipoproteinemia, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, hypertriglyceridemia, hyperlipidoproteinemia, peripheral vascular disease, angina, ischemia, and myocardial infarction.
The CETP inhibitor can be administered to the mammal at any suitable dosage (e.g., to achieve a therapeutically effective amount). For example, a suitable dose of a therapeutically effective amount of Compound I for administration to a patient will be between approximately 100 mg to about 1800 mg per day. A desirable dose is preferably about 300 mg to about 900 mg per day. A preferred dose is about 600 mg per day. The pharmacokinetics parameters (e.g., area under the concentration-time curve, maximum concentration, and the like) will, of course, vary based on the dosage administered to the mammal (e.g., human). The pharmacokinetics parameters may also be influenced by additional factors, such as the mass of the mammal and genetic components. For example, as illustrated by Examples 1-4, the bioavailability of Compound I (as indicated by Caz,
AUC..,, and AUC g..) is greater following administration to Oriental (especially Japanese) humans as compared to Caucasian humans.
If desired, the effective daily dose of the CETP inhibitor (e.g., Compound I) may be administered as two, three, four, five, six, or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. Each such sub- dose contains a therapeutically effective amount of the CETP inhibitor (e.g., Compound I).
The pharmaceutical composition, when administered to a mammal, especially a human, desirably achieves certain pharmacokinetic effects as evaluated by the maximum observed plasma concentration of the active form of CETP inhibitor (e.g., the active form of
Compound I) (C,uay), the area under the plasma concentration-time curve (AUC) from time zero up to the last quantifiable concentration (0-,) and/or from time zero to infinity (0-0) of the CETP inhibitor (e.g., the active form of Compound 1), and/or a decrease in CETP activity (as compared to CETP activity before administration of the pharmaceutical composition).
The pharmaceutical composition, at a daily dose of 300 mg, 600 mg, or 900 mg of the CETP inhibitor, particularly Compound I, administered with food, preferably achieves a Car, AUCo.iz, AUCo., and/or decrease in CETP activity in the environment of use (e.g., plasma, especially of a human), as set forth below:
Coax (300 mg daily dose): at least about 0.1 pg/mL (e.g., at least about 0.15 ng/mL, at least about 0.2 pg/mL, at least about 0.25 pg/mL, at least about 0.3 ng/mL, at least about
0.4 pg/mL, at least about 0.5 ng/mL, at least about 0.6 pg/mL, at least about 0.7 pg/mL, at
Jeast about 0.8 pg/mL, at least about 0.9 pg/mL, at least about 1 pg/mL, at Jeast about 1.1 ng/mL, at least about 1.2 pg/mL, at least about 1.3 pg/mL, at least about 1.4 pg/mL, at least about 1.5 pg/mL, at least about 1.6 pg/mL, at least about 1.7 pg/mL, or at least about 1.8 ug/ml).
Cua (600 mg daily dose): at least about 0.35 pg/mL (e.g., at least about 0.4 pg/mL, at least about 0.5 pg/mL, at least about 0.6 pg/mL, at least about 0.7 ng/mL, at least about 0.8 pg/mL, at least about 0.9 pg/mL, at least about 1 ng/mL, at least about 1.1 pg/mL, at least about 1.2 pg/mL, at least about 1.3 ng/mL, at least about 1.4 ng/mL, at least about 1.5 pg/ml, at least about 1.6 pg/mL, at least about 1.7 pg/mL, at least about 1.8 pg/mL, at least about 1.9 pg/mL, or at least about 2 pg/mL).
Cmax (900 mg daily dose): at least about 0.8 pg/mL (e.g., at least about 0.9 ng/mL, at least about 1 ng/mL, at least about 1.1 pg/mL, at least about 1.2 ng/mL, at least about 1.3 pg/mL, at least about 1.4 pg/mL, at least about 1.5 pg/mL, at least about 1.6 ng/mL, at least about 1.7 pg/mL, at least about 1.8 pg/mL, at least about 1.9 pg/mL, at Jeast about 2 pg/mL, at least about 2.1 pg/mL, at least about 2.2 pg/mL, at least about 2.3 ug/ml, at least about 2.4 ng/ml, or at least about 2.5 pg/mL).
AUC)., (300 mg daily dose): at least about 0.5 pg-h/mL (e.g., at least about 1 pg-h/mL, at least about 1.5 ug-h/mL, at least about 2 ug-h/mL, at least about 2.5 pg-h/mL, at least about 3 pg-h/mL, at least about 3.5 pg-h/mL, at least about 4 ug-h/mkL, at least about 4.5 pg/mL, at least about S pg-lVmL, at least about 5.5 pg-h/mL, at least about 6 pg-h/mL, at least about 6.5 ug-h/mL, at least about 7 ug-h/mL, at least about 7.5 ug-h/mL, at least about 8 pug-h/mL, at least about 8.5 pg-h/mL, at least about 9 png-h/mL, at least about 9.5 ug-h/mL, or at least about 10 pg-h/mL).
AUC, (600 mg daily dose): at least about 3.5 ug-h/mL (e.g., at least about 4 ng -h/mL, at least about 4.5 pg-h/mL, at least about 5 pg-h/mL, at least about 5.5 pg-h/ml, at least about 6 pg-h/mL, at least about 6.5 pg-h/mL, at least about 7 pg-h/mL, at least about 7.5 pg h/mL, at least about 8 pig-h/mL, at least about 8.5 ug h/mL, at least about 9 ug-h/mL, at least about 9.5 ug-h/mL, at least about 10 ng-h/mL, at least about 10.5 pg-hmL, at least about 11 pg-h/mL, at least about 11.5 ug-h/mL, at least about 12 ug-h/ml., at least about 12.5 ug-h/mL, at least about 13 pg-h/mL, at least about 13.5 ug-h/mL, at least about 14 ug h/mL, at least about 14.5 pg-h/mL, or at least about 15 pug-h/mL).
AUC(o42) (900 mg daily dose): at least about 7.5 ug-h/mL, at least about 8 pg -h/mL, at least about 8.5 pg-h/mL, at least about 9 pg-h/mL, at least about 9.5 pg-h/mL, at least about 10 pg-h/mL, at least about 10.5 pg-h/mL, at least about 11 pg-h/mL, at least about 11.5 pg-h/ml, at least about 12 pg-h/mL, at least about 12.5 ug-h/mL, at least about 13 pg-h/mL, at least about 13.5 pg-h/mL, at least about 14 ug-h/mL, at least about 14.5 pg-h/mL, at least about 15 pg-h/mL, at least about 15.5 pg-h/mL, at least about 16 pg-h/mL, at least about 16.5 pg/mL, at least about 17 pg-h/mL, at least about 17.5 pg-h/mL, at least about 18 pg-h/mL, at least about 18.5 pg-h/mL, at least about 19 pg-h/mL, at least about 19.5 pug-h/mL, or at least about 20 pg-h/mL).
AUC. (300 mg daily dose): at least about 0.5 pg-h/mL (e.g., at least about 1 pug -h/mL, at least about 1.5 pg-h/mL, at least about 2 pg-h/mL, at least about 2.5 pg-h/mL, at least about 3 pg-h/mL, at least about 3.5 pg-h/mL, at least about 4 ug-h/mL, at least about 4.5 pg-h/mL, at least about 5 ug-h/mL, at least about 5.5 pg-h/mL, at least about 6 png-h/mL, at least about 6.5 ug-h/mL, at least about 7 pg-h/mL, at least about 7.5 pg-h/mL, at least about 8 pug-h/mL, at least about 8.5 pug-h/mL, at least about 9 ng-h/mL, at least about 9.5 pg-h/mL, or at least about 10 pg-h/mL).
AUC. (600 mg daily dose): at least about 3.5 pg-h/mL (e.g, at least about 4 ng-h/mL, at least about 4.5 ug-h/mL, at least about 5 ng-h/mL, at least about 5.5 pug-h/mL, at least about 6 pg-h/mL, at least about 6.5 pg-h/mL, at least about 7 ug h/mL, at least about 7.5 ug-h/mL, at least about 8 pg-h/mL, at least about 8.5 pg-h/mL, at least about 9 pg-h/mL, at least about 9.5 pg-h/mL, at least about 10 pg-h/mL, at least about 10.5 ng-h/mL, at least about 11 pg-h/nL, at least about 11.5 ug-h/mL, at least about 12 pg-h/mL, at least about 12.5 pg-h/mL, at least about 13 pg-h/mL, at least about 13.5 pg-h/mL, at least about 14 ng-h/mL, at least about 14.5 pg-h/mL, or at least about 15 ug-h/mL).
AUC(0-») (900 mg daily dose): at least about 7.5 ug-h/mL, at least about 8 ug-h/mL, at least about 8.5 pg-h/mL, at least about 9 ug-h/mL, at least about 9.5 ng-h/mL, at least about 10 pg-h/mL, at least about 10.5 pg-h/mL, at least about 11 pg-h/ml, at least about 11.5 ug-h/mL, at least about 12 pg-h/mL, at least about 12.5 ug-h/mL, at least about 13 yg-h/mL, at least about 13.5 ug-h/mL, at least about 14 pg-h/mL, at least about 14.5 ug-h/mL, at least about at least about 15 pg-h/mL, at least about 15.5 ug-h/mL, at least about 16 pg-h/mL, at least about 16.5 pg-h/mL, at least about 17 pg-h/mL, at least about 17.5 pg-h/mL, at least about 18 pg-h/mL, at least about 18.5 pg/mL, at least about 19 pg-h/mL, at least about 19.5 ug-h/mL, or at least about 20 ug-h/mL).
Decrease in CETP activity (300 mg daily dose): at least about 10% (e.g., at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, or at least about 75% or more) relative to the
CETP activity before administration of the pharmaceutical composition.
Decrease in CETP activity (600 mg daily dose): at least about 25% (e.g., at least about 30%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about
80%, or at least about 85% or more) relative to the CETP activity before administration of the pharmaceutical composition.
Decrease in CETP activity (900 mg daily dose): at least about 35% (e.g, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% or more) relative to the CETP activity before administration of the pharmaceutical composition.
The pharmaceutical composition, at a daily dose of 300 mg, 600 mg, or 900 mg of the CETP inhibitor, particularly Compound I, administered without food, preferably achieves a Cypax, AUCq.1z, AUC, and/or decrease in CETP activity as set forth below:
Cmax (300 mg daily dose): at least about 0.05 pg/mL (e.g, at least about 0.1 pg/mL, at least about 0.15 pg/mL, at least about 0.2 pg/mL, at least about 0.25 ng/ml, at least about 0.3 pg/mL, at least about 0.4 pg/mL, at least about 0.5 pg/mL, at least about 0.6 ug/ml, at least about 0.7 pg/mL, at least about 0.8 pg/mL, at least about 0.9 pg/mL, at least about 1 pg/mL, at least about 1.1 pg/mL, at least about 1.2 ng/mL, at least about 1.3 ng/mL, at least about 1.4 pg/mL, or at least about 1.5 pg/mL).
Coax (600 mg daily dose): at least about 0.15 pg/mL (¢.g., at least about 0.2 pg/mL, at least about 0.25 pg/mL, at least about 0.3 pg/mL, at least about 0.4 pg/mL, at least about 0.5 ug/mL, at least about 0.6 ng/mL, at least about 0.7 pg/mL, at least about 0.8 ng/mL, at least about 0.9 ng/mL, at least about 1 pg/mL, at least about 1.1 pg/mL, at least about 1.2 ng/mL, at least about 1.3 pg/mL, at least about 1.4 pg/mL, at least about 1.5 pg/mL, at least about 1.6 pg/mL, at least about 1.7 pg/mL, at least about 1.8 pg/mL, at least about 1.9 pg/mL, or at least about 2 pg/ml).
Cuax (900 mg daily dose): at least about 0.35 pg/mL (e.g., at least about 0.4 pg/mL, atleast about 0.5 pg/mL, at least about 0.6 ng/mL, at least about 0.7 pg/mL, at least about 0.8 pg/mL, at least about 0.9 pg/mL, at least about 1 pg/mL, at least about 1.1 pg/mL, at least about 1.2 pg/mL, at least about 1.3 pg/mL, at least about 1.4 pg/mL, at least about 1.5 pg/mL, at least about 1.6 pg/mL, at least about 1.7 pg/mL, at least about 1.8 pg/mL, at least about 1.9 pg/mL, or at least about 2 pg/mL).
AUC, (300 mg daily dose): at least about 0.1 pg-h/mL (e.g, at least about 0.2 ug-h/mL, at least about 0.3 pug-h/mL, at least about 0.4 pg-h/mL, at least about 0.5 pug-h/mL, at least about 0.6 pg-h/mL, at least about 0.7 pg-h/mL, at least about 0.8 ug-h/mL, at least about 0.9 ug-h/mL, at least about 1 pug-h/mL, at least about 1.5 ug-h/mL, at least about 2 pg-h/mL, at least about 2.5 ug-h/mlL, at least about 3 ug-h/mL, at least about 3.5 pg-h/mlL, at least about 4 ug-h/mL, at least about 4.5 pg-h/mL, at least about 5 pg-h/mL, at least about 5.5 pg-h/mL, at least about 6 pg-h/mL, at least about 6.5 ug-h/mL, at least about 7 pg-h/mL, or at least about 7.5 ug-h/mL).
AUCo., (600 mg daily dose): at least about 1.5 ug-h/mL (e.g., at least about 2 ug-h/mL, at least about 2.5 pg-h/mL, at least about 3 pg-h/mL, at least about 3.5 pg-h/mL, at least about 4 pg-h/mL, at least about 4.5 pug-h/mL, at least about 5 pg-h/mL, at least about 5.5 pg-h/mL, at least about 6 pg-h/mL, at least about 6.5 pg-h/mL, at least about 7 ug-h/mL, at least about 7.5 pg-h/mL, at least about 8 pg h/mlL, at least about 8.5 pg-h/mL, at least about 9 pg-h/mL, at least about 9.5 ug-h/mL, or at least about 10 pg-h/mL).
AUC) (900 mg daily dose): at least about 5.5 ng-h/mL (e.g., at least about 6 pg h/mL, at least about 6.5 ug-h/mL, at least about 7 ug-h/mL, at least about 7.5 ug-h/mL, at least about 8 pg-h/mL, at least about 8.5 pg-h/mL, at least about 9 pg-h/mL, at least about 9.5 ug-h/mL, at least about 10 pg-h/mL, at least about 10.5 pg-h/mL, at least about 11 pg-h/mL, at least about 11.5 ng-h/mL, at least about 12 pg-h/mL, at least about 12.5 pg-h/mL, at least about 13 pg-h/mL, at least about 13.5 ug-h/mL, at least about 14 ug-h/mL, at least about 14.5 pg-h/mL, at least about at least about 15 pg-h/mL, at least about 15.5 pg -h/mL, at least about 16 pg-h/mL, at least about 16.5 pg-h/mL, at least about 17 pg-h/mL, or atleast about 17.5 pug-h/mL).
AUC (300 mg daily dose): at least about 0.1 pg-h/mL (e.g., at least about 0.2 pg-h/mL, at least about 0.3 ng-h/mL, at least about 0.4 ug-h/mL, at least about 0.5 pg-h/mL, at least about 0.6 pg-h/mL, at least about 0.7 ug-h/mL, at least about 0.8 ug-h/mL, at least about 0.9 pg-h/mL, at least about 1 pg-h/mL, at least about 1.5 pg h/mL, at least about 2 pg-h/mL, at least about 2.5 pg-h/mL, at least about 3 pg-h/mL, at least about 3.5 pg-h/mL, at least about 4 jg-h/mL, at least about 4.5 pg-h/mL, at least about 5 pg h/mL, at least about 5.5 pg-h/mL, at least about 6 pg-h/mL, at least about 6.5 ug-h/mL, at least about 7 ug-h/mL, or at least about 7.5 pg-h/mL).
AUC.» (600 mg daily dose): at least about 1.5 pg-h/mlL (e.g., at least about 2 pg-h/mL, at least about 2.5 ug-h/mL, at least about 3 pg-h/mL, at least about 3.5 pg-h/mL, at least about 4 pg-h/mL, at least about 4.5 pg-h/mL, at least about 5 ug-h/mL, at least about 5.5 pg-h/mL, at least about 6 pug-h/mL, at least about 6.5 ug-h/mL, at least about 7 pg-h/mL, at least about 7.5 ug-h/mL, at least about 8 pg-h/mL, at least about 8.5 ug-h/mL, at least about 9 pg-h/mL, at least about 9.5 pg-h/mL, or at least about 10 ug-h/mL).
AUC(0-) (900 mg daily dose): at least about 5.5 ug-h/mL (e.g., at least about 6 pg-h/ml, at least about 6.5 pg-h/mL, at least about 7 ug-h/mL, at least about 7.5 pg-h/mL, at least about 8 pg-h/mlL, at least about 8.5 pug-h/mL, at least about 9 pg-h/mL, at least about 9.5 pg-h/mL, at least about 10 pg-h/mL, at least about 10.5 ug-h/mkL, at least about 11 pg/mL, at least about 11.5 pg-h/mL, at least about 12 pg-h/mL, at least about 12.5 ug-h/mL, at least about 13 pg-h/mL, at least about 13.5 pg-h/mL, at least about 14 pg-h/mL, at least about 14.5 pg-h/ml., at least about 15 ug-h/mL, at least about 15.5 pg-h/mL, at least about 16 pug-h/mL, at least about 16.5 pg-h/mL, at least about 17 pg-h/mL, or at least about 17.5 pg-h/mL).
Decrease in CETP activity (300 mg daily dose): at least about 2.5% (e.g., at least about 5%, at least about 7.5%, at least about 10%, at Jeast about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50% or more) relative to the CETP activity before administration of the pharmaceutical composition.
Decrease in CETP activity (600 mg daily dose): at least about 5% (e.g., at least about 7.5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, or at least about 60% or more) relative to the CETP activity before administration of the pharmaceutical composition.
Decrease in CETP activity (900 mg daily dose): at least about 12.5% (e.g., at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, or at least about 75% or more) relative to the
CETP activity before administration of the pharmaceutical composition.
Furthermore, the pharmaceutical composition of the invention, when administered to a patient, desirably results in one or more (€.g., two or three) of the following conditions in the patient: (a) an inhibition of cholesteryl ester transfer protein (CETP) activity in the patient relative to pretreatment CETP activity (as described above), (b) an increase in high density lipoprotein cholesterol (HDL-C) level in the patient relative to pretreatment HDL-C level, and (c) a decrease in the ratio of total cholesterol to HDL-C level (TC/HDL-C) in the patient relative to pretreatment TC/HDL-C. The term “pretreatment” refers to the time prior (desirably immediately prior) to administration of the active compounds of the composition of the invention to the patient. The desired extent of changes in each of the foregoing conditions in the patient relative to pretreatment are recited below.
The HDL-C level is measured using standard techniques known in the art.
Preferably, the HDL-C level following the administration (e.g. after 4 weeks of treatment) of 300 mg of the CETP inhibitor, particularly Compound I, is increased by about 10% or more relative to pretreatment HDL-C level (e.g., about 12.5% or more, about 15% or more, about 17.5% or more, about 20% or more, about 22.5% or more, about 25% or more, about 27.5% or more, about 30% or more, about 32.5% or more, about 35% or more, about 37.5% or more, about 40% or more, about 42.5% or more, about 45% or more, about 47.5% or more, or about 50% or more).
The HDL-C level following the administration (e.g. after 4 weeks of treatment) of 600 mg of the CETP inhibitor, particularly Compound I, is increased by about 15% or more relative to pretreatment HDL-C level (e.g., about 17.5% or more, about 20% or more, about 22.5% or more, about 25% or more, about 27.5% or more, about 30% or more, about 32.5% or more, about 35% or more, about 37.5% or more, about 40% or more, abort 42.5% or more, about 45% or more, about 47.5% or more, about 50% or more, about 52.5% or more, or about 55% or more).
The HDL-C level following the administration (e.g. after 4 weeks of treatment) 0f 900 mg of the CETP inhibitor, particularly Compound I, is preferably increased by about 20% relative to pretreatment HDL-C level (e.g., about 22.5% or more, about 25% or more, about 27.5% or more, about 30% or more, about 32.5% or more, about 35% or more, about 37.5% or more, about 40% or more, about 42.5% or more, about 45% or more, about 47.5% or more, about 50% or more, about 52.5% or more, about 55% or more, about 57.5% or “more, or about 60% or more).
Total cholesterol (TC) is determined using standard techniques known in the art.
Preferably, the TC/HDL-C ratio following the administration (e.g. after 4 weeks of trzatment) of 300 mg of the CETP inhibitor, particularly Compound I, is decreased by about 5% or more relative to the pretreatment TC/HDL-C ratio (e. g.. about 7.5% or more, about 10% or more, about 12.5% or more, about 15% or more, about 17.5% or more, about 20% or more, about 22.5% or more, about 25% or more, about 27.5% or more, about 30% or more, about 32.5% or more, or about 35% or more).
The TC/HDL-C ratio following the administration (c.g. after 4 weeks of treatment) of 600 mg of the CETP inhibitor, particularly Compound I, is decreased by about 10% or more relative to the pretreatment TC/HDL-C ratio (e.g., about 12.5% or more, about 15% or more, about 17.5% or more, about 20% or more, about 22.5% or more, about 25% or more, about 27.5% or more, about 30% or more, about 32.5% or more, about 35% or more, or about 37.5% or more, or about 40% or more).
The TC/HDL-C ratio following the administration (e.g. after 4 weeks of treatment) of 900 mg of the CETP inhibitor, particularly Compound 1, is decreased by about 15% or more relative to the pretreatment TC/HDL-C ratio (e.g., about 17.5% or more, about 20% or more, about 22.5% or more, about 25% or more, about 27.5% or more, about 30% or more, about 32.5% or more, about 35% or more, or about 37.5% or more, about 40% or more, about 42.5% or more, or about 45% or more).
Moreover, the invention provides a kit comprising a pharmaceutical composition comprising a therapeutically effective amount of a CETP inhibitor (e.g, Compound I) anda water-insoluble concentration-enhancing additive, prescribing information, and a container.
The prescribing information can be prescribing information conforming to the methods of
AMENDED SHEET: 13 JULY 2006 the invention and/or as otherwise discussed herein. The prescribing information preferably includes advice to a patient regarding the administration of the CETP inhibitor (e.8.,
Compound I) with food, especially to improve the bioavailability of the CETP inhibitor.
The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.
EXAMPLE 1
This example illustrates the absorption of a CETP inhibitor (e.g., Compound I) when administered in a pharmaceutical composition according to the invention.
For this study, Caucasian male human subjects were administered 100 mg, 300 mg, 600 mg, 900 mg, 1200 mg, 1500 mg, or 1800 mg of Compound 1, or placebo, after a standard breakfast. The tablets administered at each dose level are recited in Table 1.
Table 1 - Tablets Administered at Each Dose Level
Dose Level (mg)
Compound I 100 | 1 x 100 mg 1 x placebo 300 1 x300 mg 600 | 2x300 mg
Lo 900 1200 1500 5% 300mg | 5 x placebo 1800 } 6 x 300 mg 6 x placebo
The uncoated white tablets were prepared using standard tableting procedures.
The 100 mg tablets comprised 100 mg of Compound 1, 6 mg of hydroxypropylmethyl cellulose 2910 as a binder, 175.1 mg of microcrystalline cellulose and 116.8 mg of lactose as diluents, 18 mg talc and 1.2 mg of magnesium stearate as lubricants, and 39.9 mg of crospovidone and 90 mg of low substituted hydroxypropyl cellulose as disintegrants.
The 300 mg tablets comprised 300 mg of Compound I, 18 mg of hydroxypropylmethyl cellulose 2910 as a binder, 18 mg of talc and 1.2 mg of magnesium stearate as lubricants, and 119.8 mg of crospovidone and 90 mg of low substituted hydroxypropyl cellulose as disintegrants.
The placebo tablets comprised 175.1 mg of microcrystalline cellulose and 262.7 mg of lactose as diluents, 18 mg of talc and 1.2 mg of magnesium stearate as lubricants, and 90 mg of low substituted hydroxypropyl cellulose as a disintegrant. The placebo tablets were similar in appearance to the tablets comprising Compound L
Treatments were administered orally with 150 mL water while standing.
Subjects were not allowed to lie supine for 2 hours after dose administration, except for study procedures.
Doses were administered at similar times for each subject in each treatment period. Dosing commenced at approximately 08:30 hours. All subjects fasted from food and fluids (with the exception of water) from 22:00 hours on the day prior to dosing (Day - 1) until breakfast on Day 1, and during the evening prior to the post-study visit until laboratory safety evaluations had been performed on the following day. Water could be consumed at any time during the study, with the exception of the period up to 2 hours post- dose, when no fluids were permitted.
Subjects received a standard breakfast about 45 minutes prior to dosing. The meal was eaten at a steady rate over a 15 minute period so that the meal was completed 30 minutes before dosing. The standard breakfast consisted of the following: 200 mL orange juice
Two packets of cereal (approximately 60 2)
Two slices of wholemeal toast 10 g low fat spread (one packet) g jam (one packet) 20 242 mL full fat milk (approximately 250 g)
Total energy content: 711 Kcal
Total fat content: 15.72 g (19.9% of total calories)
Total protein: 20.82 g (11.7% total calories)
Blood samples for pharmacokinetic analysis were taken immediately prior to dosing and at the following times after dosing: 1,2,4,6,7,10, 12, 24, and 36 hours post- dose.
The following pharmacokinetic parameters were calculated for the different dosage profiles and are defined as follows: tonax ‘Time of maximum observed plasma concentration of the active form of Compound I;
Cua Maximum observed plasma concentration of the active form of
Compound I; tin Half-life of plasma concentration of the active form of Compound I;
AUC, Area under the plasma concentration-time curve (AUC) from time zero up to the last quantifiable concentration (0-t,), of the active form of Compound I; and
AUC.» AUC from time zero to infinity (0-cc)
Pharmacokinetic parameters were log-transformed by analysis and assessed using SAS® Least Square Means derived from a three-way analysis of variance (ANOVA) fitting effects for subject, treatment, and period. Treatment comparisons were made by calculating the difference and 95% confidence intervals (CIs) of the difference of the log
SAS® Least Square Means between parameters for the respective treatments. The differences and Cls of the differences were back-transformed for reporting purposes.
The plasma concentration of the active form of Compound I was determined by the following assay. Plasma samples were isolated from patients treated with Compound I.
The plasma samples were treated with sodium hydroxide (Wako Pure Chemical Industries,
Ltd.) to convert active forms of Compound I in the plasma to the thiol form (i.e., Compound
II). The plasma sample next was treated with dithiothreitol (DTT) (Wako Pure Chemical
Industries, Ltd.) to prevent the oxidation of thiol groups (i.€., to maintain thiol groups in a reduced state). N-ethylmaleimide (NEM) (Wako Pure Chemical Industries, Ltd.) was added to stabilize the thiol form (i.e., Compound II) by, it is belicved, blocking the free sulfhydryl group by the derivatization to an NEM-adduct. The sample then was analyzed using High
Performance Liquid Chromatography (HPLC). Finally, the results of the HPLC analysis of the plasma sample were compared to a known standard to determine the plasma concentration of the active form of Compound I. The standard of known concentration was prepared essentially as described above, with the exception that human plasma was isolated from humans who were not treated with Compound I. These “blank plasma” samples were combined with a known amount of Compound I.
The mean test results for plasma pharmacokinetic parameters, AUC yo (pg-h/mL), AUC o., (ug-W/mL), Cunax (ng/mL), ti2 (1), and tua (h), of the active form of
Compound I are summarized in Table 2.
Table 2 — Plasma Pharmacokinetic Parameters of the Active Form of S-[2-([[1-(2- ethylbutyl)cyclohexyljcarbonyljamino)phenylj 2-methylpropanethioate ) Dose of Compound I
AUC (04)* | NA | 0735 | 408 | 7.71 (ug-h/mL) (NA) | (45.6) (22.3) (14.7) (19.0) (16.1) (25.4)
AUC (00) | NC | NA | 461 | 874 | 211 | 247 (ug-h/mL) (NO) (NA) (19.0) (15.9) (16.4) (14.9) (21.6) (ng/mL) (53.0) (51.1) (41.7) (17.2) (31.5) (28.9) (35.8) ot 3.00 2.00 3.00 4.00 5.00 4.00 5.00 u fo (0.500- | (200- | (200- | (2.00 | (400- | (4.00- | (4.00- 6.00) 4.00) 6.00) 6.00) 6.00) 6.00) 6.00)
I (norm) (51.8) (62.2) (40.4) (17.1) (32.1) (25.4) (37.3)
AUC (0-t)* | NA | 0.186 0.631 (norm) NA) | 57.0) | 224) | 14) | (42) | (14D | (241) (norm) (NC) (NA) (19.3) (22.7) (21.9) (15.1) | (184) _ NC NA 11.8 13.1 12.8 11.1 12.4 h) Ne) | (NA) (7.09- (10.8- (10.6- (8.84- (9.32- 17.2) 14.9) 16.4) 14.5) 20.3) * = geometric mean (geometric coefficient of variation %) 1 =median (min-max) t = harmonic mean (min-max)
NA = not applicable
NC = not calculable norm = normalized for dose and body weight (mg/kg)
As demonstrated by the data in Table 2, a pharmaceutical composition comprising a CETP inhibitor can achieve a maximum observed plasma concentration (Cuax) of the CETP inhibitor, or active form thereof, in the bloodstream of a mammal of at least about 0.1 pg/mL at a dose of 300 mg when administered with food. For example, at a dose of 300 mg of Compound I, the Cues Was about 0.16 pg/mL.
The data in Table 2 also demonstrates that a pharmaceutical composition comprising a CETP inhibitor can achieve a maximum observed plasma concentration (Cpa) of the CETP inhibitor, or active form thereof, in the bloodstream of a mammal of at least about 0.35 pg/mL and an area under the plasma concentration-time curve (AUCo.) Of at least about 3.5 pug-h/mL, at a dose of 600 mg when administered with food. For example, at a dose of 600 mg of Compound 1, the Cuax Was about 0.5 pg/mL, and the AUC.» Was about ug-h/mL. 5 Additionally, the data indicates that a pharmaceutical composition comprising a
CETP inhibitor can achieve a maximum observed plasma concentration (Cay) of at least about 0.8 pg/mL and an area under the plasma concentration-time curve (AUCq..,) of at least about 7.5 pug-h/mL, at a dose of 900 mg when administered with food. For example, at a dose of 900 mg of Compound I, the Cnax Was about 0.9 ng/mL, and the AUC, was about 9 pg-h/mL.
EXAMPLE 2
The effect of food on the absorption of a CETP inhibitor in patients was identified in a study designed to compare the bioavailability of 900 mg of Compound I orally administered to Caucasian male volunteers with and without food.
For this study each of six subjects received Compound I at a dose level of 900 mg in each of two treatment periods, once with food (after a standard brealfast) and once in the fasted state. There was a minimum of 7 days between each treatment period. This interval of 7 days between treatments was considered appropriate for eliminating any within-subject carryover effects.
The subjects received 900 mg of Compound I by administration of 3 tablets of 300 mg each. Tablet preparation and administration procedures were as described as in
Example 1, with the following exceptions.
Doses were administered at similar times for each subject in each treatment period. Dosing commenced at approximately 08:30 hours. All subjects fasted from food and fluids (with the exception of water) from 22:00 hours on the day prior to dosing (Day 1) until breakfast on Day 1 (for subjects receiving Compound I in the fed state (i.e., with food)) or lunch-time on Day 1 (for subjects receiving Compound I in the fasted state), and during the evening prior to the post-study visit until laboratory safety evaluations had been performed on the following day. Water could be consumed at any time during the study, with the exception of the period up to 2 hours post-dose, when no fluids were permitted.
When subjects were administered Compound I in the fed state, they received a standard brealkfast about 45 minutes prior to dosing as described in Example 1.
The mean test results for plasma pharmacokinetic parameters, AUC gw (ug-h/mL), AUC o., (ng/mL), Cuax (ng/mL), ti2 (), and ty. (h), of the active form of
Compound I are summarized in Table 3.
Table 3 — Plasma Pharmacokinetic Parameters of the Active Form of S-[2-({[1-(2- ethylbutyl)cyclohexyl] carbonyljamino)phenyl] 2-methylpropanethioate
Treatment Protocol Ratio mer ey _(ng'h/mL) (46.9) (19.0)
AUC (0-0) * 7.97 157 _(ug-h/mL) (46.7) (17.4)
Cane * | 0.423 226 (ng/mL) | 37.1) (26.1) oo (2.00-6.00) (2.00-6.00) (14.1-22.4) (12.6-18.6) * = geometric mean (geometric coefficient of variation %) * = median (min-max)
NA =not applicable 1 = harmonic mean (min-max)
The absorption of the active form of Compound I was relatively slow, with the time of maximum observed plasma concentration occurring at between 4 and 5 hours after administration of Compound I. As is apparent from Table 3, the time of maximum observed plasma concentration was similar after administration of Compound I with and without food. Additionally, the half life of the active form of Compound I was determined to be similar after administration of the drug with and without food.
Several of the pharmacokinetic parameters, however, were affected by the administration of Compound I with food. These include AUC tz, AUC 0.0, and Ciuax, which were 65%, 57%, and 126% higher, respectively, when Compound I was administered with food as compared with the administration of Compound I in the fasted state. These increases are noticeably apparent when the geometric mean plasma concentrations of the active form of Compound I were plotted in linear form in Figure 1 and plotted in semi- logarithmic form in Figure 2.
The observed increases in pharmacokinetic parameters when Compound 1 is administered with food indicate an increase in the bioavailability of the active form of the drug when compared to administration of the drug under fasted conditions.
Therefore, this example demonstrates that an increase in bioavailability of a
CETP inhibitor results when the CETP inhibitor is administered with food relative to administration without food.
EXAMPLE 3
This example further illustrates the absorption of a CETP inhibitor (¢.£.,
Compound I) when administered ina pharmaceutical composition according to the invention.
Japanese male human subjects were administered 100 mg, 300 mg, 600 mg, 900 mg, 1200 mg, 1500 mg, or 1800 mg of Compound I, or placebo, following a standard breakfast. Administration, dosing, and sampling schedules were commensurate with those described in Example 1. The tablets were prepared as described in Example 1.
The mean test results for plasma pharmacokinetics parameters of the active form of Compound I, AUC oo (ng-h/mL), Cuex (ng/mL), and toa (h), as well as typ a (h) and ty)
PB, are summarized in Table 4. tina signifies the half-life in the a-phase of plasma concentration of the active form of Compound I, and ti, B signifies the half-life in the B- phase of plasma concentration of the active form of Compound I.
Table 4 — Plasma Pharmacokinetic Parameters of the Active Form of S-12-(1[1-(2-
LL ethylbutyl)cyciohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate
Parameter 100mg 0120+ | 2.133+ | 10.458 + | 14.936 + | 24.197 + | 43.062 + | 40.057 +
AUC (0-0) (ng Wm) (1.0) (17.8) (87.2) (124.5) | (201.6) | (3589) | (333.8) ne 0.013 | 008 | 0378 | 0521 1.136 | 2227 1.550 (ng/mL) (1.0) (6.7) (27.1) (45.2) (71.8) (143.9) | (134.6) tiz a
Fama Ere (h) 5.1 2.1 2.1 3.7 1.5 1.9
As demonstrated by the data in Table 4, a pharmaceutical composition comprising a CETP inhibitor can achieve a maximum observed plasma concentration (Cy)
of the CETP inhibitor, or active form thereof, in the bloodstream of a mammal of at least about 0.1 pg/mL and an area under the plasma concentration-time curve (AUC) of at least about 0.5 pg-h/mL, at a dose of 300 mg when administered with food. For example, at a dose of 300 mg of Compound I, the Cpa Was about 0.2 pg/mL, and the AUC,., was about 2pgh/mL.
The data in Table 4 also demonstrates that a pharmaceutical composition comprising a CETP inhibitor can achieve a maximum observed plasma concentration (Cuax) of at least about 0.35 pg/mL and an area under the plasma concentration-time curve (AUC) of the CETP inhibitor, or active form thereof, in the bloodstream of a mammal of at least about 3.5 pg-h/mL, at a dose of 600 mg when administered with food. For example, at a dose of 600 mg of Compound I, the Cy. was about 1 pg/mL, and the AUC... was about 10 pg-h/mL.
Additionally, the data indicates that a pharmaceutical composition comprising a
CETP inhibitor can achieve a maximum observed plasma concentration (Cp) Of at least about 0.8 pg/mL and an area under the plasma concentration-time curve (AUC) of at least about 7.5 ug-h/mL, at a dose of 900 mg when administered with food. For example, at a dose of 900 mg of Compound I, the Cua was about 1.7 pg/mL, and the AUC, was about 15 pg-h/mL.
EXAMPLE 4
In a similar study to that described in Example 2, the effect of food on the absorption of the active form of Compound I in patients was identified in a study designed to compare the bioavailability of 600 mg of Compound I orally administered to Japanese male volunteers with and without food.
Administration, dosing, and sampling schedules were commensurate with those described in Example 2. However, patients were administered 600 mg (rather than 9200 mg) of Compound I with and without food. Patients were administered two tablets of 300 mg each. The tablets were prepared as described in Example 1.
The mean test results for plasma pharmacokinetics parameters of the active form of Compound I, AUC ¢., (pg-h/mL), Cas (ng/mL), and tps (h), as well as tip a (h) and ti,
B(h), are summarized in Table 5.
AMENDED SHEET: 13 JULY 2006 ’
Table 5 — Plasma Pharmacokinetic Parameters of the Active Form of S-[2-({[1-(2- ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate
Treatment Protocol (ng /mL) (0.52) (1.00) (ng/mL) (0.31) (1.00) tw® | 22211 sels 55+14 27s06 tun (0) 20.6+3.0 | sae21
Pharmacokinetics parameters, such as maximum observed plasma concentration (Cue) and area under the plasma concentration-time curve from time zero to infinity (AUC), were affected by administration of Compound I with food. The Conax Value after administration of 600 mg of Compound I was 1.029 ng/mL when administered with food and only 0.316 pg/mL when administered without food. The AUC.» value after administration of 600 mg of Compound 1 was 10.458 pg h/mL when administered with food and only 5.395 pg h/mL when administered without food. Thus, the Cmax and AUC. were about 3 and 2 times higher, respectively, when the patients were administered the CETP inhibitor with food as compared to without food.
The observed increases in the pharmacokinetic parameters when Compound 1 is administered with food indicate that the active form of the drug is more readily absorbed when administered with food, such as after a meal. Thus, the administration of a CETP inhibitor (e.g., Compound I) with food results in an increase in the bioavailability of the active form of the drug relative to the administration of the CETP inhibitor under fasted conditions.
EXAMPLE 5
This example illustrates the effect of the administration of a CETP inhibitor (e.g.,
Compound I) on CETP activity when administered in a pharmaceutical composition according to the invention.
Caucasian male human patients were orally administered 100 mg, 200 mg, 600 mg, 900 mg, 1200 mg, 1500 mg, 1800 mg of Compound I, or placebo, following breakfast.
Administration, dosing, and sampling schedules were substantially similar to those described in Example 1. The tablets were prepared as described in Example 1.
The procedure for determining CETP activity was substantially similar to the procedures described in Tollefson et al., Methods Enzymol., 129, 797-816 (1986), and Kato et al., J. Biol. Chem., 264, 4082-4087 (1989).
CETP activity and changes from baseline (pre-dose) were measured, and the resulting data is summarized in Table 6 as percentage change from baseline. ‘Table 6 — Mean (S.D.) Changes from Baseline (Pre-dose) in CETP Activity
Percent Changes from Pre-dose (standard deviation) i Cl Ea (15.8) | @4 | G1 | G1) (G0) | 40) | (44 (8.9)
Compound | (15.4) | 3.8) 34) | (56) | 3.0) | 40) 53) | 22)
Compound I | (104) | 2.1) | (3.3) 4.3) G4) | B34 | 39) 6.1)
Compound I | (22.9) | (4.0) | (59) (13.1) | (134) | (14.6) | (103) (8.9)
Compound I | (17.2) | (3.8) (14.1) | 11.8) | O09 | 92) (5.2) (10.8)
Compound I | (5.8) 24) | 9.8) | (6.3) @n | 64 | GD (8.8)
Compound I | (124) | (2.6) | 21.6) QL) | 907 | 0.0) | (6.1) (49)
Compound I | (16.0) | (3.7) | (14.7) (162) | (152) | (14.3) | (10.9) (5.1)
As demonstrated by the data in Table 6, a pharmaceutical composition comprising a CETP inhibitor can achieve a decrease in CETP activity of at least about 10% relative to pre-dose levels at a dosc of 300 mg. For example, 6 hours after the administration of 300 mg of Compound I, CETP activity had decreased by 13%.
The data in Table 6 also demonstrates that a pharmaceutical composition comprising a CETP inhibitor can achieve a decrease in CETP activity of at least about 25% relative to pre-dose levels at a dose of 600 mg. For example, 6 hours after the administration of 600 mg of Compound I, CETP activity had decreased by 36%.
Additionally, the data indicates that a pharmaceutical composition comprising a
CETP inhibitor can achieve a decrease in CETP activity of at least about 35% relative to placebo at a dose of 900 mg. For example, 6 hours after the administration of 900 mg of
Compound I, CETP activity had decreased by 55%.
EXAMPLE 6
The effect of food on the absorption of the active form of Compound I in
Caucasian male patients was identified in a study designed to compare the CETP activity following the oral administration of 900 mg of Compound I with and without food.
Administration, dosing, and sampling schedules were substantially similar to those described in Example 1.
The procedure for determining CETP activity is described in Example 5.
CETP activity and changes from baseline (pre-dose) over time were measured, and the resulting data is summarized in Table 7. The mean changes from baseline (pre- dose) in CETP activity over time are set out in the plot of Figure 3.
Table 7 — Mean (S.D.) Changes from Baseline (Pre-dose) in CETP Activity
Percent Changes from Pre-dose (standard deviation)
Treatment | Pre- 1h 2h 6h 24h Post- mre CTE subjects (17.0) 23) | (132) | (14.0) | (11.1) (ary | (4.5) 96 (16.0) (2.2) 2.4) 22) | 3.1) 4.7) (3.8)
A clear difference in CETP activity was observed when Compound [ was administered with and without food. Inhibition of CETP activity was much more marked in the fed treatment protocol as compared with the fasted treatment protocol. For example, 70 between 4 and 24 hours post-dose, there was a significant decrease in CETP activity in the fed versus the fasted state. Such a decrease in CETP activity indicates increased bioavailability of the active form of the drug when administered with food as compared to administration of the drug without food.
The relationships between plasma concentrations of the active form of
Compound I and inhibition of CETP activity for the fed and fasted states are illustrated by the plots of Figures 4 and 5, respectively. As plasma concentrations of the active form of
Compound | increased, the inhibitory effect on CETP increased (i.e., CETP activity decreased).
EXAMPLE 7
This example further illustrates the effect of the administration of a CETP inhibitor (e.g., Compound I) on the CETP activity when administered in a pharmaceutical composition according to the invention.
Japanese male human patients were orally administered 100 mg, 300 mg, 600 mg, 900 mg, 1200 mg, 1500 mg, or 1800 mg of Compound 1, or placebo, following breakfast.
Administration, dosing, and sampling schedules were commensurate with those described in Example 1. The tablets were prepared as described in Example 1.
Relative CETP activities (calculated as a percentage of baseline CETP activity) and standard deviations (SD) were measured, and the resulting data is summarized in Table 8.
Table 8 — Relative CETP Activity
Percent CETP Activity Relative to Pre-dose (standard
Treatment deviation) > lh | 2h ERE 8h Post- study (0.0) 3.4) | 4.3) (3.8) (3.1) 4.0) (5.7) (9.6) (0.0) (1.9) (3.3) (2.5) (2.8) (2.2) 4.7) (11.1) (0.0) (3.9) (5.5) 4.2) (3.9) (5.6) (3.8) (9.9) (0.0) (1.9) 9.2) | (13.4) | (6.6) (8.3) (5.7) (73) (0.0) (2.9) (9.3) (9.0) 8.1) (7.9) (7.6) (5.6)
GEAR EAE
(0.0) 2.0) | (17.0) | (5.9) (3.6) (4.3) (8.2) (8.8) 1s00mg | 100 | 100.8 96.9 (0.0) 33) | (132) | (7.9) (1.7) 2.1) (5.7) (6.8) (0.0) (11.5) | (8.7) (1.7) (0.9) (1.4) (3.0) (6.6)
As demonstrated by the data in Table 8, a pharmaceutical composition comprising a CETP inhibitor can achieve a decrease in CETP activity of at least about 10%
relative to pre-dose levels at a dose of 300 mg. For example, 6 hours after the administration of 300 mg of Compound I, CETP activity is about 80.5% of the pre-dose value. Therefore, CETP activity has decreased by about 19.5% following the administration of Compound I.
The data in Table 8 also demonstrates that a pharmaceutical composition comprising a CETP inhibitor can achieve a decrease in CETP activity of at least about 25% relative to pre-dose levels at a dose of 600 mg. For example, 6 hours after the administration of 600 mg of Compound I, CETP activity is only about 38% of the pre-dose value. Therefore, CETP activity has decreased by about 62% following the administration of Compound 1.
Additionally, the data indicates that a pharmaceutical composition comprising a
CETP inhibitor can achieve a decrease in CETP activity of at least about 35% relative to pre-dose CETP activity at a dose of 900 mg. For example, 4 hours after the administration of 900 mg of Compound 1, CETP activity is only about 24% of the pre-dose value. Thus,
CETP activity has decreased by about 76%.
EXAMPLE 8
In a similar study to that described in Example 6, the effect of food on the absorption of the active form of Compound I in Japanese male patients was identified in a study designed to compare the relative CETP activity following the oral administration of 600 mg of Compound I with and without food.
Administration, dosing, and sampling schedules were commensurate with those described in Examples 1 and 6. However, patients were administered 600 mg (rather than 900 mg as in Example 6) of Compound I with and without food. Patients were administered two tablets of 300 mg each. The tablets were prepared as described in Example 1.
Relative CETP activities (calculated as a percentage of baseline CETP activity) and standard deviations (SD) were measured, and the resulting data is summarized in Table
Table 9 — Relative CETP Activity peer | EPR
Protocol (0.0) (1.9) (92) | (134) | (66) (8.3) (5.7) (7.3) (0.0) (3.6) 2.1) 3.1) 2.0) (4.6) (3.0) (2.8)
A clear difference in CETP relative activity was observed when Compound I was administered with and without food, consistent with the results discussed in Example 2.
Inhibition of CETP activity was much more marked in the fed treatment protocol as compared with the fasted treatment protocol. For example, between 4 and 24 hours post- dose, there was a significant decrease in CETP activity in the fed versus the fasted state.
Specifically, the inhibition of CETP activity following the administration of Compound I with food reached its peak at 6 hours post-administration with 37 6% CETP activity relative to baseline. In contrast, the inhibition of CETP activity following the administration of
Compound I without food reached its peak at 8 hours post-administration with 87.8% CETP activity relative to baseline. Such a decrease in the relative CETP activity following the administration of Compound I with food indicates increased bioavailability of the active form of the drug when administered with food as compared to the administration of the drug without food.
EXAMPLE 9
This example illustrates the effect of the administration of Compound I on CETP activity and lipid levels in healthy individuals.
About 200 volunteers (men and women) were randomized to receive placebo or to receive 300 mg (low dose), 600 mg (medium dose) or 900 mg (high dose) of Compound I per day for 4 weeks. Each patient took three tablets after breakfast each day for 4 weeks.
Patients either took three placebo tablets (placebo); one 300 mg tablet and two placebo tablets (low dose); two 300 mg tablets and one placebo tablet (medium dose); or three 300 mg tablets (high dose). Tablet preparation was as described as in Example 1.
The testing period consisted of (a) a run-in period of 4 weeks, followed by (b) 4 weeks of treatment, and (c) 4 weeks of monitoring. Blood samples were drawn after an overnight fast. For CETP activity assays, blood was drawn before Compound I intake and during and after treatment, HDL-C was determined with a heparin MnCl, precipitation reagent and LDL-C was calculated by the Friedewald formula (see, de Grooth et al., supra).
CETP activity was measured as described in Example 5.
Table 10 describes the values of the assayed properties ((mean) = standard deviation) at baseline (i.e., before administration of Compound I). Table 11 describes the absolute changes in the assayed properties after 4 weeks of treatment. The data points for absolute changes from baseline (i.e., before administration of Compound I) in CETP activity, total cholesterol (TC), HDL-C, LDL-C, and total cholesterol/HDL-C (TC/HDL-C) ratio are provided below. Analysis was done by fitting an ANOVA model with separate treatment effects for the four groups (i.e., placebo, 300 mg, 600 mg, or 900 mg of
Compound I).
Table 10 — Baseline Characteristics
Assayed Treatment Protocol (n= 50) (n=48) (n=48) (n=52) (% of control)
TC (mmol/l) | 56:11 (mmol/L) (mmol/L) ratio
Table 11 — Absolute Changes in Assayed Properties According to Dose of S-[2-([{1-(2- ethylbutyl)cyclohexyl]carbonyljamino)phenyl] 2-methylpropanethioate after 4 Weeks
Treatment
Assayed Treatment Protocol (n=50) (n=48) (n=47) (n=52) (% of control) = (mmol/L)
LDL-C 20.1£0.5 20.240.5 (mmol/L)
TC/HDL-C 0.2+0.6 20.7+0.8' -0.9+0.8F ____ ratio * P<0.01; T P<0.001; ¥ P<0.0001 (each group versus placebo)
S
As demonstrated by the data in Tables 10 and 11, a pharmaceutical composition comprising a CETP inhibitor can achieve an increase in HDL-C levels of about 10%, about 15%, and about 20% at dose levels of 300 mg, 600 mg, and 900 mg of Compound I, respectively, following daily treatment for 4 weeks. For example, HDL-C levels were increased by about 15%, about 26%, and about 34% relative to baseline levels of the 300 mg, 600 mg, and 900 mg treatment groups, respectively.
Tables 10 and 11 also illustrate that the TC/HDL-C ratio can be decreased by about 5%, about 10%, and about 15% at dose levels of 300 mg, 600 mg, and 900 mg of
Compound I, respectively, following daily treatment for 4 weeks. For example, the
TC/HDL-C ratios were decreased by about 13%, about 18%, and about 23% relative to baseline levels of the 300 mg, 600 mg, and 900 mg treatment groups, respectively.
The data in Tables 10 and 11 also demonstrate that a pharmaceutical composition comprising a CETP inhibitor can achieve a decrease in CETP activity of at least about 10%, about 25%, and about 35% relative to pre-dose levels at a dose levels of 300 mg, 600 mg, or 900 mg of the CETP inhibitor (e.g, Compound I), respectively, following daily administration of the CETP inhibitor with food for 4 weeks. For example,
CETP activity decreased by about 17%, about 33%, and about 39%, relative to baseline : levels of the 300 mg, 600 mg, and 900 mg treatment groups, respectively.
EXAMPLE 10
The following example illustrates the method of manufacturing the formulation comprising 300 mg of Compound I described in Example 1.
In Step 1, Compound I was pulverized by jet mill. A particle size distribution of
Jess than about 10 pum (e.g., about 5 pm) of pulverized Compound I was tested by the use of an in-process control.
In Step 2, the pulverized Compound I was mixed with crospovidone by drum mixer, resulting in a mixed powder.
In Step 3, the mixed powder of Step 2 was passed through a screen #12 approximately three times.
In Step 4, the screened, mixed powder of Step 3 was pre-mixed by wet granulator.
In Step 5, hydroxypropylmethylcellulose 2910 was dissolved in purified water using a propeller mixer.
In Step 6, the mixed powder of Step 4 was granulated using the solution of Step 5 as a binder in the wet granulator. This step yielded four batches of granulated material.
In Step 7, two of the four batches of granulated material of Step 6 were transferred to a fluidized bed dryer and dried. The process was repeated for the remaining two batches.
In Step 8, the granulated material of Step 7 was passed through a screen #22.
Moisture content and particle size distribution were tested by an in-process control.
In Step 9, all of the dried granulated material of Step 8 was mixed by drum mixer.
In Step 10, the granulated material of Step 9 was mixed with low substituted hydroxypropyl cellulose by drum mixer to yield mixed granulated material.
In Step 11, the mixed granulated material of Step 10 was mixed with talc and magnesium stearate by drum mixer. Content uniformity, specific volume, and angle of repose were tested by an-process control.
In Step 12, the mixed granulated material was compressed by a tableting machine. Content uniformity, tablet hardness, thickness, and friability were assayed.
Additionally, dissolution and weight variation tests were performed.
This example demonstrates that a formulation comprising 300 mg Compound I, hydroxypropylmethyl cellulose 2910, talc, magnesium stearate, crospovidone, and low substituted hydroxypropyl cellulose (as described in Example 1) can be formed into an oral dosage form.
All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
The use of the terms “a” and “an” and “the” and similar referents in the context : of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value 18 incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non- claimed element as essential to the practice of the invention.
Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
Claims (23)
1. A pharmaceutical composition comprising a cholesteryl ester transfer protein inhibitor and crospovidone.
2. The pharmaceutical composition of claim 1, wherein a major portion of the cholesteryl ester transfer protein inhibitor is crystalline.
3. The pharmaceutical composition of claim 1, wherein the cholesteryl ester transfer protein inhibitor is substantially crystalline.
4, The pharmaceutical composition of claim 1, wherein the cholesteryl ester transfer protein inhibitor is crystalline.
5. A pharmaceutical composition comprising a substantially crystalline cholesteryl ester transfer protein inhibitor and a water-insoluble concentration-enhancing additive, wherein the cholesteryl ester transfer protein inhibitor has the structure of Formula I 0 PY Formula] R NH Xq S——7Z Xo X4 X3 or a prodrug compound, pharmaceutically acceptable salt, enantiomer, stereoisomer, hydrate, or solvate thereof, in which R represents a substituted or unsubstituted Cs.jo cycloalkyl group or a substituted or unsubstituted Cs.g cycloalkenyl group; each of Xj, Xs, Xs, and X4 may be the same or different and represents a hydrogen atom; a halogen atom; a Cys alkyl group; AMENDED SHEET: 13 JULY 2006 a halo-C,_4 alkyl group; a Cj. alkoxy group; a cyano group; a nitro group; an acyl group; or an aryl group; and Z represents a hydrogen atom; —YR;, wherein Y represents -CO- or ~CS—, and R, represents a substituted or unsubstituted straight chain or branched C,.1o alkyl! group; a C4 alkoxy group; a C4 alkylthio group; a substituted or unsubstituted amino group; a substituted or unsubstituted ureido group; a substituted or unsubstituted Cs.jo cycloalkyl group; a substituted or unsubstituted Cs.jo cycloalkyl Cp allyl group; a substituted or unsubstituted aryl group; a substituted or unsubstituted aralkyl group; a substituted of unsubstituted arylalkenyl group; a substituted or unsubstituted arylthio group; a substituted or unsubstituted 5- or 6-membered heterocyclic group having 1-3 nitrogen, oxygen, or sulfur atoms; or a substituted or unsubstituted 5- or 6-membered heteroarylaklyl group; or —S—R,, wherein : R, represents a substituted or unsubstituted C4 alkyl! group or a substituted or unsubstituted aryl group.
6. The composition of claim 5, wherein the cholesterol ester transfer protein mhibitor is crystalline. AMENDED SHEET: 13 JULY 2006
7. The composition of claim 5, wherein the cholesterol ester transfer protein inhibitor and water-insoluble concentration-enhancing additive are in a weight ratio of about 2:1 to about 9:1.
S 8. The composition of claim 7, wherein the water-insoluble concentration- enhancing additive is crospovidone.
9. The composition of claim 5, wherein the cholesteryl ester transfer protein inhibitor is a compound selected from the group consisting of N-(Z-mercaptophenyl)-1-isopentylcyclohexanecarboxamide; N-(2-mercaptophenyl)-1-methylcyclohexanecarboxamide; N-(2-mercaptophenyl)-1-isopentylcyclopentanecarboxamide; N-(2-mercaptophenyl)-1-isopropylcyclohexanecarboxamide; N-(4,5-dichloro-2-mercaptophenyl)-1-isopentylcyclohexanecarboxamide; N-(4,5-dichloro-2-mercaptophenyl)-1-isopentylcyclopentanecarboxamide; N-(2-mercapto-3-methylphenyl)-1-isopentylcyclohexanecarboxamide; N-(2-mercapto-4-methylphenyl)-1-isopentyleyclohexanecarboxamide; S-[2-(1-isopentylcyclchexanecarbonylamino)phenyl] thioacetate; S-[2-(1-methylcyclohe:zanecarbonylamino)phenyl] 2,2-dimethylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl] 2,2-dimethylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl] 2-acetylamino-3- phenylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl] 3-pyridinethiocarboxylate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl] chlorothioacetate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl] methoxythioacetate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl] thiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl] phenoxythioacetate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl] 2-methylthiopropionate; S-[2-(1-1sopentylcyclohexanecarbonylamino)phenyl] 4-chlorophenoxythioacetate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl] cyclopropanethiocarboxylate; S-[2-(1-1sopentylcyclohexanecarbonylamino)phenyl] 2-acetylamino-4- carbamoylthiobutyrate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl] 2-hydroxy-2-methylthiopropionate; S-[2(1-isopentylcyclopentanecarbonylamino)phenyl] 2,2-dimethylpropionate; S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl] thioacetate; S-[4,5-dichloro-2-(1-1sopentylcyclohexanecarbonylamino)phenyl] 2,2- dimethylthiopropionate; AMENDED SHEET: 13 JULY 2006
S-[4,5-dichloro-2-(1-isopentylcyclopentanecarbonylamino)phenyl] 2,2- dimethylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)-4-trifluoromethylphenyl] 2,2-dimethylthiopropionate;
O-methyl S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl] monothiocarbonate; S-[2-(1-methylcyclohexanecarbonylamino)phenyl] S-phenyl dithiocarbonate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl] N-phenylthiocarbamate; S-[4,5-dichloro-2-(1-cyclopropylcyclohexanecarbonylamino)phenyl] 2,2-
dimethyithiopropionate; S-[4,5-dichloro-2-(1-pentylcyclohexanecarbonylamino)phenyl] 2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-cyclopropylmethylcyclohexanecarbonylamino)phenyl] 2,2- dimethylthiopropionate; S-[4,5-dichloro-2-(1-cyclohexylmethylcyclohexanecarbonylamino)phenyl] 2,2- dimethylthiopropionate; S-[4,5-dichloro-2-(1-isopropylcyclohexanecarbonylamino)phenyl] 2,2- dimethylthiopropionate; S-[4,5-dichloro-2-(1-isopentylcycloheptanecarbonylamino)phenyl] 2,2- dimethylthiopropionate; S-[4,5-dichloro-2-(1-isopentylcyclobutanscarbonylamino) phenyl] 2,2-
dimethylthiopropionate; S-[2-(1-1sopentylcyclohexanecarbonylamino)-4-nitrophenyl] 2,2-dimethylthiopropionate; S-[4-cyano-2-(1-isopentylcyclohexanecarbonylamino)phenyl] 2,2-dimethylthiopropionats; S-[4-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl] 2,2-dimethylthiopropionate; S-[5-chlore-2-(1-isopentylcyclohexanecarbonylamino)pbenyl] 2,2-dimethylthiopropionate;
S-[4-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl] 2,2-dimethylthiopropionate; S-[4,5-difluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]} 2,2-
dimethylthiopropionate; S-[5-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl] 2,2-dimethylthiopropionate; N-(2-mercaptophenyl)-1-ethylcyclohexanecarboxamide;
N-(2-mercaptophenyl)-1-propylcyclohexanecarboxamide; N-(2-mercaptophenyl)-1-butylcyclohexanecarboxamide; N-(2-mercaptophenyl)-1-1sobutylcyclohexanecarboxamide; S-[2-(1-1sopentylcyclohexanecarbonylamino) phenyl] cyclohexanethiocarboxylate; S-[2-(1-1sopentylcyclohexanecarbonylamino)phenyl] thiobenzoate;
S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl] S-carboxythiopentanoate; S-[2-(1-1sopentylcyclohexanecarbonylamino)-4-methylphenyl] thioacetate; N-(2-mercaptophenyl)-1-(2-ethylbutyl)cyclohexanecarboxamide;
AMENDED SHEET: 13 JULY 2006
S-[2-([[1 ~(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate; S-[2-(1-isobutyleyclohexanecarbonylamino)phenyl] 2-methylthiopropionate; S-[2-[1-(2-ethylbutyl)cyclobexanecarbonylamino]phenyl] 1-acetylpiperidine-4- thiocarboxylate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl] thioacetate; S-[2-{1-(2-ethylbutyl)cyclohexanecarbonylaminolphenyl] 2,2-dimethylthiopropionate; S-[2-[1 -(2-ethylbutyl)cyclohexanecarbonylamino]phenyl] methoxythioacetate; S-[2-1 -(2-ethylbutyl)cyclohexanecarbonylamino]phenyl] 2-hydroxy-2-methylpropionate; S-{2-[1 ~(2-ethylbutyl)cyclohexanecarbonylamino]phenyl] 4-chlorophenoxythioacetate; S-2< I-isobutylcyclohexanecarbonylamino)phenyl] 4-chlorophenoxythioacetate; and S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl] 1-acetylpiperidine-4-thiocarboxylate; or a prodrug compound, a pharmaceutically acceptable salt, a hydrate, or a solvate thereof.
10. The composition of claim 5, wherein the cholesteryl ester transfer protein inhibitor is a prodrug that forms S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] thiol in vivo.
11. The composition of claim 5, wherein the cholesteryl ester transfer protein inhibitor is S~[2-([[1 -(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2- methylpropanethioate.
12. The composition of claim 11, wherein the cholesteryl ester transfer protein inhibitor is crystalline.
13. The composition of claim 11, wherein the cholesterol ester transfer protein inhibitor and the water-insoluble concentration-enhancing additive are in a weight ratio of about 2:1 to about 9:1.
14. The composition of claim 13, wherein the water-insoluble concentration- enhancing additive is crospovidone.
15. A pharmaceutical composition of any one of claims 1-14 for use in a method for the treatment or prophylaxis of a cardiovascular disorder in a mammal, which comprises administering to the mammal a therapeutically effective amount of the composition. AMENDED SHEET: 13 JULY 2006
16. The composition of claim 15, wherein the cardiovascular disorder is selected from the group consisting of atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, and vascular complications of diabetes, obesity or endotoxemia.
17. The composition of claim 15, wherein the cardiovascular disorder is selected from the group consisting of cardiovascular disease, coronary heart disease, coronary artery disease, hypoalphalipoproteinemia, hyperbetalipoproteinemia, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, hypertriglyceridemia, hyperlipidoproteinemia, peripheral vascular disease, angina, ischemia, and myocardial infarction.
18. The composition of claim 15, wherein a maximum concentration of the cholesteryl ester transfer protein inhibitor, or active form thereof, in the bloodstream of a mammal is al least about 0.35 pg/mL post-treatment relative to pretreatment when the cholesteryl ester transfer protein inhibitor is S-[2-([[1-(2- ethylbutyl)cyclohexyl]carbonyl]lamino)phenyl] 2-methylpropanethioate administered at a daily dose of 600 mg with food.
19. The composition of claim 15, wherein a maximum concentration of the cholesteryl ester transfer protein inhibitor, or active form thereof, in the bloodstream of a mammal is at least about 0.8 ng/mL post-treatment relative to pretreatment when the cholesteryl ester transfer protein inhibitor is S-[2-([[1-(2- ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate administered at a daily dose of 900 mg with food.
20. The composition of claim 15, wherein an area under the plasma concentration- time curve AUC. of the cholesteryl ester transfer protein inhibitor, or active form thereof, in the bloodstream of a mammal is at least about 3.5 pg.h/mL post-treatment relative to pretreatment when the cholesteryl ester transfer protein inhibitor is S-[2-([[1-(2- AMENDED SHEET: 13 JULY 2006 ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate administered at a daily dose of 600 mg with food.
21. The composition of claim 15, wherein an area under the plasma concentration- time curve AUC. of the cholesteryl ester transfer protein inhibitor, or active form thereof, in the bloodstream of a mammal is at least about 7.5 pg.h/mL post-treatment relative to pretreatment when the cholesteryl ester transfer protein inhibitor is S-[2-([[1-(2- ethylbutyl)cyclohexyl]carbonylJamino)phenyl] 2-methylpropanethioate administered at a daily dose of 900 mg with food.
22. The composition of claim 15, wherein cholesteryl ester transfer protein activity in the bloodstream of a mammal is inhibited post-treatment by at least about 25% relative to CETP activity pretreatment when the cholesteryl ester transfer protein inhibitor is S-[2-({{1-(2-ethylbutyl)cyclohexyl]carbonyl]Jamino)phenyl] 2-methylpropancthioate administered at a daily dose of 600 mg with food.
23. The compostion of claim 15, wherein cholesteryl ester transfer protein activity in the bloodstream of a mammal is inhibited post-treatment by at least about 35% relative to CETP activity pretreatment when the cholesteryl ester transfer protein inhibitor is S-[2-([[1- (2-ethylbutyl)cyclohexyl]carbonyl]Jamino)phenyl] 2-methylpropanethioate administered at a daily dose of 900 mg with food. AMENDED SHEET: 13 JULY 2006
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45529303P | 2003-03-17 | 2003-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200508159B true ZA200508159B (en) | 2007-03-28 |
Family
ID=36707296
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200508160A ZA200508160B (en) | 2003-03-17 | 2004-03-17 | Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl) 2-methyl-propanethioate |
ZA200508159A ZA200508159B (en) | 2003-03-17 | 2004-03-17 | Pharmaceutical compositions of CETP inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200508160A ZA200508160B (en) | 2003-03-17 | 2004-03-17 | Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl) 2-methyl-propanethioate |
Country Status (2)
Country | Link |
---|---|
CN (3) | CN1777419B (en) |
ZA (2) | ZA200508160B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009137879A1 (en) * | 2008-05-14 | 2009-11-19 | Agriculture Victoria Services Pty Ltd | Orally administrable dosage forms comprising angiogenin and uses thereof |
US20110004011A1 (en) * | 2009-07-01 | 2011-01-06 | Declan Costello | Novel process |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2894445B2 (en) * | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Compounds effective as CETP activity inhibitors |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
HUP0400263A2 (en) * | 2001-06-21 | 2005-03-29 | Pfizer Products Inc. | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
EP1269994A3 (en) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
EP1404300B1 (en) * | 2001-06-22 | 2009-09-30 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
AR038375A1 (en) * | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITIONS OF INHIBITORS OF THE PROTEIN OF TRANSFER OF ESTERES DE COLESTERILO |
-
2004
- 2004-03-17 ZA ZA200508160A patent/ZA200508160B/en unknown
- 2004-03-17 CN CN200480007445.7A patent/CN1777419B/en not_active Expired - Fee Related
- 2004-03-17 ZA ZA200508159A patent/ZA200508159B/en unknown
- 2004-03-17 CN CN 200710096744 patent/CN101036636A/en active Pending
- 2004-03-17 CN CN 200480007444 patent/CN1761463A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN1777419B (en) | 2010-04-28 |
CN101036636A (en) | 2007-09-19 |
CN1777419A (en) | 2006-05-24 |
ZA200508160B (en) | 2007-01-31 |
CN1761463A (en) | 2006-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20140243414A1 (en) | Pharmaceutical compositions of cetp inhibitors | |
JP5586896B2 (en) | How to induce terminal differentiation | |
US20080045599A1 (en) | Method for Increasing the Bioavailability of the Active Form of S-[2-([[1-(2-Ethylbutyl)Cyclohexyl]Carbonyl] Amino)Phenyl] 2-Methylpropanethioate | |
CN106604725B (en) | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, or treating or preventing the development of diabetes | |
IL174310A (en) | Compositions having cholesteryl ester transfer protein inhibitory activity and remnant lipoprotein production inhibitory activity and uses thereof | |
ZA200206072B (en) | Aniline-derived ligands for the thyroid receptor. | |
JP2018507874A (en) | NK-3 receptor antagonist for therapeutic or cosmetic treatment of excess body fat | |
ZA200508159B (en) | Pharmaceutical compositions of CETP inhibitors | |
RU2318504C2 (en) | Cetp-inhibitor-containing pharmaceutical compositions | |
EP1772147A2 (en) | Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate | |
AU2008201550B2 (en) | Method of inhibiting remnant lipoprotein production | |
RU2588133C2 (en) | Niacin mimetics and method for use thereof |